Cantel Medical (CMD) 10-Q10 Dec 132014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Oct. 31, 2013	Nov. 29, 2013
Document and Entity Information	'	'
Entity Registrant Name	'CANTEL MEDICAL CORP	'
Entity Central Index Key	'0000019446	'
Document Type	'10-Q	'
Document Period End Date	31-Oct-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--07-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	41,299,183
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Oct. 31, 2013	Jul. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$28,453,000	$34,076,000
Accounts receivable, net of allowance for doubtful accounts of $1,610 at October 31 and $1,265 at July 31	57,648,000	52,753,000
Inventories:	'	'
Raw materials	23,740,000	23,815,000
Work-in-process	7,727,000	6,945,000
Finished goods	23,873,000	23,407,000
Total inventories	55,340,000	54,167,000
Deferred income taxes	4,128,000	4,129,000
Prepaid expenses and other current assets	5,724,000	4,428,000
Income taxes receivable	'	1,107,000
Total current assets	151,293,000	150,660,000
Property and equipment, net	46,565,000	46,465,000
Intangible assets, net	73,512,000	75,929,000
Goodwill	211,429,000	211,618,000
Other assets	3,019,000	2,999,000
Total assets	485,818,000	487,671,000
Current liabilities:	'	'
Current portion of long-term debt	10,000,000	10,000,000
Accounts payable	14,124,000	13,322,000
Compensation payable	9,277,000	14,032,000
Accrued expenses	10,999,000	10,417,000
Deferred revenue	12,100,000	11,380,000
Dividends payable	1,858,000	'
Income taxes payable	1,630,000	'
Total current liabilities	59,988,000	59,151,000
Long-term debt	72,000,000	85,000,000
Deferred income taxes	22,176,000	21,186,000
Other long-term liabilities	1,220,000	1,202,000
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred Stock, par value $1.00 per share; authorized 1,000,000 shares; none issued	'	'
Common Stock, par value $.10 per share; authorized 75,000,000 shares; October 31 - 45,452,795 shares issued and 41,299,722 shares outstanding; July 31 - 45,181,655 shares issued and 41,138,121 shares outstanding	4,545,000	4,518,000
Additional paid-in capital	138,732,000	134,853,000
Retained earnings	213,089,000	203,762,000
Accumulated other comprehensive income	10,713,000	10,977,000
Treasury Stock, at cost; October 31 - 4,153,073 shares; July 31 - 4,043,534 shares	-36,645,000	-32,978,000
Total stockholders' equity	330,434,000	321,132,000
Total liabilities and stockholders' equity	$485,818,000	$487,671,000

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Oct. 31, 2013	Jul. 31, 2013
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Jul. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS	'	'
Accounts receivable, allowance for doubtful accounts (in dollars)	$1,610	$1,265
Preferred Stock, par value (in dollars per share)	$1	$1
Preferred Stock, authorized shares	1,000,000	1,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value (in dollars per share)	$0.10	$0.10
Common Stock, authorized shares	75,000,000	75,000,000
Common Stock, shares issued	45,452,795	45,181,655
Common Stock, shares outstanding	41,299,722	41,138,121
Treasury Stock, shares	4,153,073	4,043,534

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012
CONDENSED CONSOLIDATED STATEMENTS OF INCOME	'	'
Net sales	$118,272	$99,681
Cost of sales	66,773	55,954
Gross profit	51,499	43,727
Expenses:	'	'
Selling	15,764	13,413
General and administrative	15,164	12,048
Research and development	2,259	2,294
Total operating expenses	33,187	27,755
Income before interest and income taxes	18,312	15,972
Interest expense	657	646
Interest income	-13	-13
Income before income taxes	17,668	15,339
Income taxes	6,483	5,763
Net income	$11,185	$9,576
Earnings per common share:	'	'
Basic (in dollars per share)	$0.27	$0.24
Diluted (in dollars per share)	$0.27	$0.23
Dividends per common share (in dollars per share)	$0.05	$0.04

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	'	'
Net income	$11,185	$9,576
Other comprehensive (loss) income:	'	'
Foreign currency translation, net of tax	-273	91
Unrealized holding losses on interest rate swaps arising during the period, net of tax	-21	-11
Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period, net of tax	30	34
Total other comprehensive (loss) income, net of tax	-264	114
Comprehensive income	$10,921	$9,690

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012
Cash flows from operating activities	'	'
Net income	$11,185	$9,576
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation	1,937	1,760
Amortization	2,626	2,267
Stock-based compensation expense	1,148	958
Amortization of debt issuance costs	82	89
Loss on disposal of fixed assets	125	41
Deferred income taxes	991	515
Excess tax benefits from stock-based compensation	-2,596	-913
Changes in assets and liabilities, net of assets acquired and liabilities assumed:	'	'
Accounts receivable	-4,921	-788
Inventories	-1,209	-833
Prepaid expenses and other current assets	-1,363	-2,073
Accounts payable and other current liabilities	-2,587	-6,329
Income taxes	5,333	5,100
Net cash provided by operating activities	10,751	9,370
Cash flows from investing activities	'	'
Capital expenditures	-2,182	-1,170
Proceeds from disposal of fixed assets	3	'
Other, net	-296	-70
Net cash used in investing activities	-2,475	-1,240
Cash flows from financing activities	'	'
Repayments under term loan facility	-2,500	-2,500
Repayments under revolving credit facility	-10,500	-7,500
Proceeds from exercises of stock options	114	173
Excess tax benefits from stock-based compensation	2,596	913
Purchases of treasury stock	-3,619	-1,578
Net cash used in financing activities	-13,909	-10,492
Effect of exchange rate changes on cash and cash equivalents	10	42
Decrease in cash and cash equivalents	-5,623	-2,320
Cash and cash equivalents at beginning of period	34,076	30,186
Cash and cash equivalents at end of period	$28,453	$27,866

Basis_of_Presentation

Basis of Presentation	3 Months Ended
Basis of Presentation	Oct. 31, 2013
Basis of Presentation	'
Basis of Presentation	'
	Note 1. Basis of Presentation

	The unaudited Condensed Consolidated Financial Statements have been prepared in accordance with United States generally accepted accounting principles for interim financial reporting and the requirements of Form 10-Q and Rule 10.01 of Regulation S-X. Accordingly, they do not include certain information and note disclosures required by generally accepted accounting principles for annual financial reporting and should be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Annual Report of Cantel Medical Corp. (“Cantel”) on Form 10-K for the fiscal year ended July 31, 2013 (the “2013 Form 10-K”) and Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein.

	The unaudited interim financial statements reflect all adjustments (of a normal and recurring nature) which management considers necessary for a fair presentation of the results of operations for these periods. The results of operations for the interim periods are not necessarily indicative of the results for the full year.

	The Condensed Consolidated Balance Sheet at July 31, 2013 was derived from the audited Consolidated Balance Sheet of Cantel at that date.

	Cantel had five principal operating companies at October 31, 2013 and July 31, 2013; Medivators Inc. (“Medivators”), Crosstex International, Inc. (“Crosstex”), Mar Cor Purification, Inc. (“Mar Cor”), Biolab Equipment Ltd. (“Biolab”) and Saf-T-Pak Inc. (“Saf-T-Pak”), all of which are wholly-owned operating subsidiaries. In addition, Medivators has two foreign subsidiaries, Medivators B.V. and Medivators Asia/Pacific Ltd., which serve as our bases in Europe and Asia/Pacific, respectively, and Crosstex has a subsidiary, SPS Medical Supply Corp., as more fully described below and in Note 3 to the Condensed Consolidated Financial Statements.

	During the fourth quarter of fiscal 2013, we changed our internal reporting processes by combining our Therapeutic Filtration and Chemistries operating segments, previously reported in the Other reporting segment, with our Water Purification and Filtration reporting segment to reflect the way the Company, through its executive management, manages, allocates resources and measures the performance of its businesses. All periods presented have been recast to reflect these changes.

	As such, we currently operate our business through five operating segments: Endoscopy (through Medivators), Water Purification and Filtration (through Mar Cor, Biolab and Medivators), Healthcare Disposables (through Crosstex), Dialysis (through Medivators) and Specialty Packaging (through Saf-T-Pak). The Specialty Packaging operating segment comprises the Other reporting segment for financial reporting purposes.

	On March 22, 2013, Mar Cor entered into an agreement to acquire from Siemens Industry, Inc. and Siemens Canada Limited (collectively, “Siemens”) certain net assets of Siemens’ hemodialysis water business (the “Siemens Water Business” or the “Siemens Water Acquisition”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements. The Siemens Water Acquisition had an insignificant effect on our results of operations for the three months ended October 31, 2013 due to the size of this business in relation to our overall consolidated results of operations and is not reflected in our results of operations for the three months ended October 31, 2012. The Siemens Water Business is included in our Water Purification and Filtration segment.

	On December 31, 2012, Mar Cor acquired certain net assets of Eagle Pure Water Systems, Inc. (the “Eagle Pure Water Business” or the “Eagle Pure Water Acquisition”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements. The Eagle Pure Water Acquisition had an insignificant effect on our results of operations for the three months ended October 31, 2013 due to the small size of this business and is not reflected in our results of operations for the three months ended October 31, 2012. The Eagle Pure Water Business is included in our Water Purification and Filtration segment.

	On November 1, 2012, Crosstex acquired all the issued and outstanding stock of SPS Medical Supply Corp. (the “SPS Business” or “SPS Medical”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements. The results of operations of SPS Medical, which had an insignificant impact on our consolidated net income, are included in the three months ended October 31, 2013 and are not reflected in the three months ended October 31, 2012. The SPS Business is included in our Healthcare Disposables segment.

	During July 2013, the Company issued 15,044,000 additional shares of common stock in connection with a three-for-two stock split effected in the form of a 50% stock dividend paid on July 12, 2013 to stockholders of record on July 1, 2013. The effect of the stock split has been recognized retroactively in all share data in the Condensed Consolidated Statements of Income, Notes to the Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations.

	Throughout this document, references to “Cantel,” “us,” “we,” “our,” and the “Company” are references to Cantel Medical Corp. and its subsidiaries, except where the context makes it clear the reference is to Cantel itself and not its subsidiaries.

	Subsequent Events

	On November 5, 2013, Medivators acquired all of the issued and outstanding stock of Jet Prep Ltd. (the “Jet Prep Business” or the “Jet Prep Acquisition”), as more fully described in Note 3 to the Condensed Consolidated Financial Statements. Since this acquisition occurred after October 31, 2013, its results of operation are not included in any period presented. We expect the Jet Prep Acquisition to have an insignificant effect on our consolidated results of operations for the remainder of fiscal 2014. The Jet Prep Acquisition will be included in our Endoscopy segment.

	We performed a review of events subsequent to October 31, 2013. Based upon that review, no other subsequent events occurred that required updating to our Condensed Consolidated Financial Statements or disclosures.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Oct. 31, 2013
Stock-Based Compensation	'
Stock-Based Compensation	'
	Note 2. Stock-Based Compensation

	The following table shows the income statement components of stock-based compensation expense recognized in the Condensed Consolidated Statements of Income:

			Three Months Ended
			October 31,
			2013			2012

	Cost of sales		$	62,000		$	55,000
	Operating expenses:
	Selling		110,000			99,000
	General and administrative		964,000			792,000
	Research and development		12,000			12,000
	Total operating expenses		1,086,000			903,000
	Stock-based compensation before income taxes		1,148,000			958,000
	Income tax benefits		(412,000		)	(340,000		)
	Total stock-based compensation expense, net of tax		$	736,000		$	618,000

	The above stock-based compensation expense before income taxes was recorded in the Condensed Consolidated Financial Statements as stock-based compensation expense and an increase to additional paid-in capital. The related income tax benefits were recorded as an increase to long-term deferred income tax assets (which are netted with long-term deferred income tax liabilities) and a reduction to income tax expense. All of our stock options and stock awards (which consist only of restricted shares) are expected to be deductible for tax purposes, except for certain options and restricted shares granted to employees residing outside of the United States, and were tax-effected using the Company’s estimated U.S. effective tax rate at the time of grant.

	All of our stock options and stock awards are subject to graded vesting in which portions of the award vest at different times during the vesting period, as opposed to awards that vest at the end of the vesting period. We recognize compensation expense for awards subject to graded vesting using the straight-line basis over the vesting period, reduced by estimated forfeitures. At October 31, 2013, total unrecognized stock-based compensation expense, before income taxes, related to total nonvested stock options and stock awards was $11,580,000 with a remaining weighted average period of 25 months over which such expense is expected to be recognized. Most of our nonvested awards relate to stock awards.

	We determine the fair value of each stock award using the closing market price of our common stock on the date of grant.

	A summary of nonvested stock award activity follows:

					Weighted
			Number of		Average
			Shares		Fair Value

	Nonvested stock awards at July 31, 2013		605,767		$	11.96
	Granted		246,136		31.82
	Canceled		(1,998	)	9.02
	Vested		(286,215	)	10.31
	Nonvested stock awards at October 31, 2013		563,690		$	21.48

	For the three months ended October 31, 2013 and 2012, the Company granted 30,000 and 52,500 options, respectively.

	The fair value of each option grant was estimated on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions for options granted during the three months ended October 31, 2013 and 2012:

	Weighted-Average
	Black-Scholes Option		Three Months Ended		Three Months Ended
	Valuation Assumptions		October 31, 2013		October 31, 2012

	Dividend yield		0.28	%	0.37	%
	Expected volatility (1)		42.7	%	50.9	%
	Risk-free interest rate (2)		1.44	%	0.67	%
	Expected lives (in years) (3)		5		5

	(1) Volatility was based on historical closing prices of our common stock.
	(2) The U.S. Treasury rate on the expected life at the date of grant.
	(3) Based on historical exercise behavior.

	For the three months ended October 31, 2013 and 2012, these non-qualified options had a weighted average fair value of $12.08 and $7.27, respectively.

	The aggregate intrinsic value (i.e., the excess market price over the exercise price) of all options exercised was $671,000 and $264,000 for the three months ended October 31, 2013 and 2012, respectively.

	A summary of stock option activity follows:

					Weighted
			Number of		Average
			Shares		Exercise Price

Outstanding at July 31, 2013		403,831		$	8.25
Granted		30,000		31.81
Exercised		(27,002	)	6.01
Outstanding at October 31, 2013		406,829		$	10.14

Exercisable at July 31, 2013		351,331		$	6.94

Exercisable at October 31, 2013		341,829		$	7.53

Upon exercise of stock options or grant of stock awards, we typically issue new shares of our common stock as opposed to using treasury shares. However, during the three months ended October 31, 2012, we reissued 127,525 shares from treasury stock for the exercise of stock options and grant of stock awards.

If certain criteria are met when options are exercised or restricted stock becomes vested, the Company is allowed a deduction on its United States income tax return. Accordingly, we account for the income tax effect on such income tax deductions as a reduction of previously recorded long-term deferred income tax assets (which are netted with long-term deferred income tax liabilities) and as a reduction of income taxes payable in the year of the deduction. Excess tax benefits arise when the ultimate tax effect of the deduction for tax purposes is greater than the tax benefit on stock compensation expense which was determined based upon the award’s fair value at the time the award was granted. The differences noted above between actual tax deductions and the previously recorded long-term deferred income tax assets are recorded as additional paid-in capital. For the three months ended October 31, 2013 and 2012, income tax deductions of $3,680,000 and $1,728,000, respectively, were generated and increased additional paid-in capital by $2,596,000 and $913,000, respectively. We classify the cash flows resulting from excess tax benefits as financing cash flows in our Condensed Consolidated Statements of Cash Flows.

Acquisitions

Acquisitions	3 Months Ended
	Oct. 31, 2013
Acquisitions	'
Acquisitions	'
	Note 3. Acquisitions

	Jet Prep Ltd.

	On November 5, 2013, our Medivators subsidiary acquired all the issued and outstanding capital stock of Jet Prep Ltd., an Israeli private company that developed the Jet Prep Flushing Device, a novel single-use irrigation and aspiration catheter to improve visualization during colonoscopy procedures. The device has FDA 510(k) and CE Mark clearances and is ready for immediate commercialization by our global endoscopy sales force. Total consideration for the transaction, excluding transaction costs, was approximately $5,350,000 plus contingent consideration based on a percentage of sales above a minimum threshold over a seven year period. The Jet Prep Acquisition will be included in our Endoscopy segment.

	The principal reasons for the acquisition were (i) to address a market need for an effective technology that improves colonoscopy visualization through the use of irrigation and suction, (ii) to expand our endoscopy product portfolio further bolstering the Medivators brand in the gastrointestinal (GI) suite, (iii) to further expand our research and development capability by adding accomplished engineers to our existing research and development team and (iv) the expectation that the acquisition will be accretive to our earnings per share in fiscal 2015 and beyond.

	Siemens’ Hemodialysis Water Business

	On March 22, 2013, Mar Cor and Siemens entered into asset purchase agreements under which Mar Cor acquired certain net assets of Siemens’ hemodialysis water business primarily consisting of customer service agreements for over 600 dialysis customers in the United States and Canada. Such service agreements had contributed over $9 million in revenue to Siemens in calendar year 2012 (unaudited) and were assigned from Siemens to Mar Cor on an individual customer by customer basis to ensure a seamless transition. The acquisition date of the Siemens Water Business was July 30, 2013, which is when the majority of the customer service agreements were transferred and therefore control of the business had been achieved. The total consideration for the transaction, excluding transaction costs of $362,000, was $8,300,000, which was paid on March 22, 2013.

	The purchase price was allocated to the assets acquired and assumed liabilities based on estimated fair values as follows:

			Final
	Net Assets		Allocation
	Current assets		$	728,000
	Property, plant and equipment		231,000
	Amortizable intangible assets:
	Customer relationships (12- year life)		4,310,000
	Current liabilities		(415,000		)
	Net assets acquired		$	4,854,000

	There were no in-process research and development projects acquired in connection with the acquisition. The excess purchase price of $3,446,000 was assigned to goodwill. Such goodwill, all of which is deductible for income tax purposes, is included in our Water Purification and Filtration reporting segment.

	The principal reasons for the acquisition were as follows: (i) the opportunity to increase service revenue and profitability of the Mar Cor service network due to improved operating leverage, (ii) the expansion of Mar Cor’s North American footprint into new geographies, (iii) the opportunity to sell capital equipment and recurring consumables to new customers and (iv) the expectation that the acquisition will be accretive to our earnings per share beyond fiscal 2013.

	The Siemens Water Acquisition had an insignificant effect on our results of operations for the three months ended October 31, 2013 due to the size of this business in relation to our overall consolidated results of operations and is not reflected in our results of operations for the three months ended October 31, 2012. The Siemens Water Business is included in our Water Purification and Filtration segment.

	Eagle Pure Water Systems, Inc.

	On December 31, 2012, we purchased substantially all of the assets of Eagle Pure Water Systems, Inc., a private company with pre-acquisition annual revenues (unaudited) of approximately $500,000 based in the suburbs of Philadelphia, Pennsylvania that provides water treatment services for laboratory, industrial and medical customers. The total consideration for the transaction was $870,000.

	The purchase price was allocated to the assets acquired and assumed liabilities based on estimated fair values as follows:

			Final
	Net Assets		Allocation
	Current assets		$	8,000
	Property, plant and equipment		70,000
	Amortizable intangible assets (3- year weighted average life):
	Customer relationships (3- year life)		150,000
	Brand names (3- year life)		18,000
	Non-compete agreement (5- year life)		32,000
	Current liabilities		(5,000		)
	Net assets acquired		$	273,000

	There were no in-process research and development projects acquired in connection with the acquisition. The excess purchase price of $597,000 was assigned to goodwill. Such goodwill, all of which is deductible for income tax purposes, is included in our Water Purification and Filtration reporting segment.

	The principal reasons for the acquisition were the strengthening of our sales and service business by adding Eagle Pure Water’s strategic Philadelphia market presence to enable us to better serve our national customers and to further expand our business into the laboratory and research segments. Such reasons constitute the significant factors that contributed to a purchase price that resulted in recognition of goodwill.

	The acquisition of Eagle Pure Water is included in our results of operations for the three months ended October 31, 2013 and is not reflected in the three months ended October 31, 2012. This acquisition had an insignificant impact on our results of operations.

	Polyp Trap

	On November 13, 2012 we acquired the intellectual property, inventory, fixed assets and exclusive distribution rights of a polyp trap product line for $486,000. This product line is used principally in the performance of endoscopy procedures for the purpose of safely and efficiently collecting tissue biopsy material. The polyp trap product line is included in our Medivators procedural product portfolio, which is part of the Endoscopy segment.

	This acquisition is included in our results of operations for the three months ended October 31, 2013 and is not reflected in the three months ended October 31, 2012. This acquisition had an insignificant impact on our results of operations.

	SPS Medical Supply Corp.

	On November 1, 2012, our Crosstex subsidiary acquired all the issued and outstanding stock of SPS Medical Supply Corp., a private company based in Rochester, New York with pre-acquisition annual revenues (unaudited) of approximately $17,500,000 that manufactures and provides biological and chemical indicators for sterility assurance monitoring services in the acute-care, alternate-care and dental markets. The SPS Business offers a wide-array of products and services that enable healthcare facilities to safely and accurately monitor and verify their sterilization practices and protocols. Total consideration for the transaction, excluding transaction costs of $157,000, was $32,500,000. In addition, we acquired the SPS manufacturing and warehouse facility in Rochester, New York for approximately $3,500,000 from an affiliate of SPS Medical. The SPS Business is included in our Healthcare Disposables segment.

	The purchase price was allocated to the assets acquired and assumed liabilities based on estimated fair values as follows:

		Final
Net Assets		Allocation
Current assets		$	4,810,000
Property, plant and equipment		3,801,000
Amortizable intangible assets (9- year weighted average life):
Customer relationships (10- year life)		8,120,000
Brand names (5- year life)		760,000
Technology (4- year life)		500,000
Non-compete agreements (6- year life)		180,000
Other assets		28,000
Current liabilities		(2,784,000		)
Noncurrent deferred income tax liabilities, net		(3,659,000		)
Net assets acquired		$	11,756,000

There were no in-process research and development projects acquired in connection with the acquisition. The excess purchase price of $24,244,000 was assigned to goodwill. Such goodwill, all of which is not deductible for income tax purposes, has been included in our Healthcare Disposables reporting segment.

The principal reasons for the acquisition were (i) to expand our sterility assurance monitoring product portfolio, (ii) to expand our market share of the dental mail-in biological monitoring industry when combined with our existing monitoring business, (iii) to expand into the acute-care hospital market and alternate care markets, (iv) to increase the likelihood of cross-selling our existing products, (v) to leverage Crosstex’ sales and marketing infrastructure and (vi) the expectation that the acquisition will be accretive to our earnings per share. Such reasons constitute the significant factors that contributed to a purchase price that resulted in recognition of goodwill.

The acquisition of the SPS Business is included in our results of operations for the three months ended October 31, 2013 and is not reflected in the three months ended October 31, 2012.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Oct. 31, 2013
Recent Accounting Pronouncements	'
Recent Accounting Pronouncements	'
	Note 4. Recent Accounting Pronouncements

	In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists,” (“ASU 2013-11”), which requires that a liability related to an unrecognized tax benefit be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. ASU 2013-11 is effective fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of ASU 2013-11 is expected to have no impact on our financial condition, results of operations or cash flows.

Derivatives

Derivatives	3 Months Ended
Derivatives	Oct. 31, 2013
Derivatives	'
Derivatives	'
	Note 5. Derivatives

	We recognize all derivatives on the balance sheet at fair value. Derivatives that are not designated as hedges must be adjusted to fair value through earnings. If the derivative is designated as a hedge, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against the change in the fair value of the hedged assets, liabilities or firm commitments through earnings or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of the change in fair value of a derivative that is designated as a hedge will be recognized immediately in earnings. As of October 31, 2013, all of our derivatives were designated as hedges. We do not hold any derivative financial instruments for speculative or trading purposes.

	Changes in the value of (i) the Euro against the United States dollar, (ii) the Canadian dollar against the United States dollar, (iii) the Singapore dollar against the United States dollar and (iv) the British pound against the United States dollar affect our results of operations because certain cash bank accounts, accounts receivable, and liabilities of our subsidiaries are denominated and ultimately settled in United States dollars, Canadian dollars, Euros, Singapore dollars or British pounds, but must be converted into their functional currency.

	In order to hedge against the impact of fluctuations in the value of (i) the Euro relative to the United States dollar, (ii) the Singapore dollar relative to the United States dollar and (iii) the British pound relative to the United States dollar on the conversion of such net assets into the functional currencies, we enter into short-term contracts to purchase Euros, Singapore dollars and British pounds forward, which contracts are one month in duration. These short-term contracts are designated as fair value hedge instruments. There were two foreign currency forward contracts with an aggregate value of $6,381,000 at October 31, 2013, which covered certain assets and liabilities that were denominated in currencies other than our subsidiaries’ functional currencies. Such contracts expired on November 30, 2013. These foreign currency forward contracts are continually replaced with new one-month contracts as long as we have significant net assets at our subsidiaries that are denominated and ultimately settled in currencies other than their functional currencies. For the three months ended October 31, 2013 and 2012, such forward contracts substantially offset the impact on operations relating to certain assets and liabilities that were denominated in currencies other than our subsidiaries’ functional currencies resulting in a net currency conversion loss, net of tax, of $62,000 and $15,000, respectively, on the items hedged. Gains and losses related to hedging contracts to buy Euros, Singapore dollars and British pounds forward are immediately realized within general and administrative expenses due to the short-term nature of such contracts. We do not currently hedge against the impact of fluctuations in the value of the Canadian dollar relative to the United States dollar because the currency impact on our Canadian and United States subsidiaries’ assets closely offset the currency impact on our Canadian and United States subsidiaries’ liabilities effectively minimizing realized gains and losses.

	The interest rate on our outstanding borrowings under our credit facilities is variable and is affected by the general level of interest rates in the United States as well as LIBOR interest rates, as more fully described in Note 9 to the Condensed Consolidated Financial Statements. In order to protect our interest rate exposure in future years, we entered into forward starting interest rate swap agreements in February 2012 in which we agree to exchange our variable interest cash flows with fixed interest cash flows provided by one of our existing senior lenders. With respect to our Term Loan Facility, the interest rate swap is for the period that began August 8, 2012 and ends July 31, 2015, initially covering $40,000,000 of borrowings based on one-month LIBOR and thereafter reducing in quarterly $2,500,000 increments consistent with the mandatory repayment schedule, and the fixed interest cash flow is at a one month LIBOR rate of 0.664%. With respect to our Revolving Credit Facility, the interest rate swap is for the period that began August 8, 2012 and ends January 31, 2014, initially covering $25,000,000 of borrowings based on one-month LIBOR and thereafter reducing semi-annually by increments of $5,000,000, and the fixed interest cash flow is at a one month LIBOR rate of 0.496%. These interest rate swap agreements have been designated as cash flow hedge instruments and have been designed to be effective in offsetting changes in the cash flows related to the hedged borrowings. As more fully described in Note 6 to the Condensed Consolidated Financial Statements, we account for the interest rate swap agreements by recording the fair value of the derivative instrument on the balance sheet as either an asset or liability, with a corresponding amount recorded in accumulated other comprehensive income. Amounts are reclassified from accumulated other comprehensive income to interest expense in the Condensed Consolidated Statements of Income in the period the hedged transaction affects earnings. At the hedge’s inception and on a regular basis thereafter, a formal assessment is performed to determine whether changes in the fair value or cash flows of the derivative instruments have been highly effective in offsetting changes in cash flows of the hedged items and whether they are expected to be highly effective in the future. This formal assessment includes a comparison of the terms of the interest rate swap agreements and hedged borrowings to ensure they coincide as well as an evaluation of the continued ability of the counterparty to the interest rate swap agreements and the Company to honor their obligations under such agreements. At October 31, 2013, our formal assessment concluded that the changes in the fair value of the derivative instruments have been and are expected to be highly effective in the future for the interest rate swap periods that began on August 8, 2012.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Oct. 31, 2013
Fair Value Measurements	'
Fair Value Measurements	'
	Note 6. Fair Value Measurements

	Fair Value Hierarchy

	We apply the provisions of Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” (“ASC 820”), for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. We define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three level fair value hierarchy to prioritize the inputs used in valuations, as defined below:

	Level 1: Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets.

	Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

	Level 3: Unobservable inputs for the asset or liability.

	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis

	As of October 31, 2013 and 2012, our financial assets that are re-measured at fair value on a recurring basis include money market funds that are classified as cash and cash equivalents in the Condensed Consolidated Balance Sheets. As there are no withdrawal restrictions, they are classified within Level 1 of the fair value hierarchy and are valued using quoted market prices for identical assets.

	In order to protect our interest rate exposure in future years, we entered into forward starting interest rate swap agreements in February 2012 in which we agree to exchange our variable interest cash flows with fixed interest cash flows provided by one of our existing senior lenders, as further described in Notes 5 and 9 to the Condensed Consolidated Financial Statements. Our interest rate swap agreements are classified within Level 2 and are valued using discounted cash flow analyses based on the terms of the contracts and the interest rate curves. Changes in fair value in these interest rate swap agreements during the three months ended October 31, 2013 were recorded in accumulated other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income. Amounts are reclassified from accumulated other comprehensive income in the period the hedged transaction affects earnings.

	On August 1, 2011 (the first day of our fiscal 2012), we recorded a $2,700,000 liability for the estimated fair value of contingent consideration and a $3,000,000 liability for the estimated fair value of a three year price floor relating to the August 1, 2011 acquisition of the endoscopy procedural product business of Byrne Medical, Inc. (the “Byrne Medical Business” or the “Byrne Acquisition”). These fair value measurements were based on significant inputs not observed in the market and thus represent Level 3 measurements.

	The fair value of the contingent consideration liability was based on future gross profit projections of the Byrne Medical Business under various potential scenarios for the two year period ended July 31, 2013 and weighting the probability of these outcomes. As such, the determination of fair value of the contingent consideration is subjective in nature and highly dependent on future gross profit projections. At the date of the acquisition, these cash flow projections were discounted using a rate of 14%. The discount rate was based on the weighted average cost of capital of the acquired business plus a credit risk premium for non-performance risk. This contingent consideration liability was adjusted periodically by recording changes in the fair value through our Condensed Consolidated Statements of Income. Based on actual gross profit results for the two year period ended July 31, 2013, contingent consideration was not earned.

	After giving effect for the Company’s three-for-two stock splits, the stock portion of the consideration paid for the Byrne Acquisition consisted of 902,528 shares of Cantel common stock and was based on the closing price of Cantel common stock on the NYSE on July 29, 2011 ($11.08). Subject to certain conditions and limitations, under a three year price floor, we agreed that if the aggregate value of the stock consideration is less than $10,000,000 on July 31, 2014, we will pay to the sellers in cash or stock (at our option) an amount equal to the difference between $10,000,000 and the then value of the shares (based on the closing price of Cantel common stock on the NYSE on July 31, 2014). This three-year price floor is a free standing financial instrument that we recorded as a liability at fair value on the date of acquisition. The 902,528 shares of Cantel common stock were (i) placed in escrow at the time of the acquisition as security for certain indemnification obligations of the sellers and (ii) subjected to a multi-year lock-up feature prohibiting the sellers from selling or otherwise transferring the shares. In November 2013, one-third of the shares were released from escrow and the lock-up feature. Likewise, the three year price floor is in the process of being modified to exclude the released shares and reduce the $10,000,000 value guaranty by one-third to $6,666,666.

	The fair value of the three year price floor liability was determined using the Black-Scholes option valuation model, which is affected by our stock price and risk free interest rate as well as assumptions regarding a number of subjective variables, including, but not limited to, the expected stock price volatility of our common stock over the expected life of the instrument and the expected dividend yield. This liability is adjusted periodically by recording changes in the fair value through our Condensed Consolidated Statements of Income, as shown below in the reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis, driven by the time value of money and changes in the assumptions that were initially used in the valuation. The decrease to the fair value of the price floor (as determined by the Black-Scholes option valuation model) was recorded as a decrease to accrued expenses or other long-term liabilities and general and administrative expenses in the Condensed Consolidated Financial Statements and was primarily due to the impact of our stock price being higher than at the time of the acquisition, the life of the price floor being less than three years and changes in the expected stock price volatility. Due to the significant increase in our stock price from $11.08 at August 1, 2011, the exclusion of the price floor on one third of the shares issued to the sellers and the short amount of time remaining until July 31, 2014, we do not expect the fair value of the price floor liability to increase during the remainder of fiscal 2014 beyond its October 31, 2013 nominal fair value.

	The fair values of the Company’s financial instruments measured on a recurring basis were categorized as follows:

			October 31, 2013
			Level 1			Level 2			Level 3		Total
	Assets:
	Cash and cash equivalents:
	Money markets		$	4,571,000		$	—		$	—	$	4,571,000
	Total assets		$	4,571,000		$	—		$	—	$	4,571,000

	Liabilities:
	Accrued expenses:
	Interest rate swap agreements		$	—		$	112,000		$	—	$	112,000
	Price floor		—			—			1,000		1,000
	Total accrued expenses		—			112,000			1,000		113,000
	Other long-term liabilities:
	Interest rate swap agreements		—			35,000			—		35,000
	Total liabilities		$	—		$	147,000		$	1,000	$	148,000

			July 31, 2013
			Level 1			Level 2			Level 3		Total
	Assets:
	Cash and cash equivalents:
	Money markets		$	4,241,000		$	—		$	—	$	4,241,000
	Total assets		$	4,241,000		$	—		$	—	$	4,241,000

	Liabilities:
	Accrued expenses:
	Interest rate swap agreements		$	—		$	133,000		$	—	$	133,000
	Total accrued expenses		—			133,000			—		133,000
	Other long-term liabilities:
	Price floor		—			—			45,000		45,000
	Interest rate swap agreements		—			29,000			—		29,000
	Total other long-term liabilities		—			29,000			45,000		74,000
	Total liabilities		$	—		$	162,000		$	45,000	$	207,000

	A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) for the last five quarters is as follows:

		Byrne			Byrne
		Contingent			Price
		Consideration			Floor			Total
Balance, July 31, 2012		$	1,500,000		$	1,037,000		$	2,537,000
Total net unrealized gains included in general and administrative expense in earnings		—			(313,000		)	(313,000		)
Transfers into or out of level 3		—			—			—
Net purchases, issuances, sales and settlements		—			—			—
Balance, October 31, 2012		1,500,000			724,000			2,224,000
Total net unrealized gains included in general and administrative expense in earnings		(1,500,000		)	(410,000		)	(1,910,000		)
Transfers into or out of level 3		—			—			—
Net purchases, issuances, sales and settlements		—			—			—
Balance, January 31, 2013		—			314,000			314,000
Total net unrealized gains included in general and administrative expense in earnings		—			(59,000		)	(59,000		)
Transfers into or out of level 3		—			—			—
Net purchases, issuances, sales and settlements		—			—			—
Balance, April 30, 2013		—			255,000			255,000
Total net unrealized gains included in general and administrative expense in earnings		—			(210,000		)	(210,000		)
Transfers into or out of level 3		—			—			—
Net purchases, issuances, sales and settlements		—			—			—
Balance, July 31, 2013		—			45,000			45,000
Total net unrealized gains included in general and administrative expense in earnings		—			(44,000		)	(44,000		)
Transfers into or out of level 3		—			—			—
Net purchases, issuances, sales and settlements		—			—			—
Balance, October 31, 2013		$	—		$	1,000		$	1,000

Assets Measured and Recorded at Fair Value on a Nonrecurring Basis

We re-measure the fair value of certain assets, such as intangible assets, goodwill and long-lived assets, including property, equipment and other assets, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, and goodwill and intangible assets with indefinite lives are reviewed for impairment at least annually. In performing a review for goodwill impairment, management first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount before proceeding to step one of the two-step quantitative goodwill impairment test, if necessary. For our quantitative test, we use a two-step process that begins with an estimation of the fair value of the related operating segments by using fair value results of the discounted cash flow methodology, as well as the market multiple and comparable transaction methodologies. The first step is a review for potential impairment, and the second step measures the amount of impairment, if any. In performing our annual review for indefinite lived intangibles, management performs a qualitative assessment, and if a quantitative assessment is necessary, we compare the current fair value of such assets to their carrying values. With respect to amortizable intangible assets when impairment indicators are present, management determines whether expected future non-discounted cash flows are sufficient to recover the carrying value of the assets; if not, the carrying value of the assets is adjusted to their fair value. With respect to long-lived assets, an assessment is made to determine if the sum of the expected future non-discounted cash flows from the use of the assets and eventual disposition is less than the carrying value. If the sum of the expected non-discounted cash flows is less than the carrying value, an impairment loss is recognized based on fair value. As the inputs utilized for our periodic impairment assessments are not based on observable market data, but are based on management’s assumptions and estimates, our goodwill, intangibles and long-lived assets are classified within Level 3 of the fair value hierarchy on a non-recurring basis. On July 31, 2013, management concluded that none of our long-lived assets, including goodwill and intangibles with indefinite-lives, were impaired and no other events or changes in circumstances have occurred during the three months ended October 31, 2013 that would indicate that the carrying amount of our long-lived assets may not be recoverable.

Disclosure of Fair Value of Financial Instruments

As of October 31, 2013 and July 31, 2013, the carrying amounts for cash and cash equivalents (excluding money markets), accounts receivable and accounts payable approximated fair value due to the short maturity of these instruments. We believe that as of October 31, 2013 and July 31, 2013, the fair value of our outstanding borrowings under our credit facilities approximated the carrying value of those obligations since the borrowing rates were at prevailing market interest rates, principally under LIBOR contracts ranging from one to twelve months.

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	3 Months Ended
Intangible Assets and Goodwill	Oct. 31, 2013
Intangible Assets and Goodwill	'
Intangible Assets and Goodwill	'
	Note 7. Intangible Assets and Goodwill

	Our intangible assets with definite lives consist of customer relationships, technology, brand names, non-compete agreements and patents. These intangible assets are being amortized using the straight-line method over the estimated useful lives of the assets ranging from 2-20 years and have a weighted average amortization period of 11 years. Amortization expense related to definite lived intangible assets was $2,626,000 and $2,267,000 for the three months ended October 31, 2013 and 2012, respectively. Our intangible assets that have indefinite useful lives, and therefore are not amortized, consist of trademarks and trade names.

	The Company’s intangible assets consist of the following:

		October 31, 2013
				Accumulated
		Gross		Amortization			Net
	Intangible assets with finite lives:
	Customer relationships	$	71,846,000	$	(26,483,000	)	$	45,363,000
	Technology	20,509,000		(9,730,000		)	10,779,000
	Brand names	12,680,000		(8,392,000		)	4,288,000
	Non-compete agreements	3,159,000		(603,000		)	2,556,000
	Patents and other registrations	1,820,000		(653,000		)	1,167,000
		110,014,000		(45,861,000		)	64,153,000
	Trademarks and trade names	9,359,000		—			9,359,000
	Total intangible assets	$	119,373,000	$	(45,861,000	)	$	73,512,000

		July 31, 2013
				Accumulated
		Gross		Amortization			Net
	Intangible assets with finite lives:
	Customer relationships	$	72,142,000	$	(25,379,000	)	$	46,763,000
	Technology	21,006,000		(9,642,000		)	11,364,000
	Brand names	12,680,000		(8,045,000		)	4,635,000
	Non-compete agreements	3,159,000		(541,000		)	2,618,000
	Patents and other registrations	1,768,000		(606,000		)	1,162,000
		110,755,000		(44,213,000		)	66,542,000
	Trademarks and trade names	9,387,000		—			9,387,000
	Total intangible assets	$	120,142,000	$	(44,213,000	)	$	75,929,000

	Estimated amortization expense of our intangible assets for the remainder of fiscal 2014 and the next five years is as follows:

	Nine month period ending July 31, 2014	$	7,856,000
	Fiscal 2015	10,229,000
	Fiscal 2016	6,989,000
	Fiscal 2017	6,413,000
	Fiscal 2018	6,136,000
	Fiscal 2019	5,813,000

	Goodwill changed during fiscal 2013 and the three months ended October 31, 2013 as follows:

				Water
				Purification			Healthcare							Total
		Endoscopy		and Filtration			Disposables		Dialysis		Other			Goodwill

	Balance, July 31, 2012	$	59,230,000	$	53,288,000		$	55,864,000	$	8,133,000	$	7,140,000		$	183,655,000
	Acquisitions	—		4,043,000			24,244,000		—		—			28,287,000
	Foreign currency translation	—		(152,000		)	—		—		(172,000		)	(324,000		)
	Balance, July 31, 2013	59,230,000		57,179,000			80,108,000		8,133,000		6,968,000			211,618,000
	Foreign currency translation	—		(87,000		)	—		—		(102,000		)	(189,000		)
	Balance, October 31, 2013	$	59,230,000	$	57,092,000		$	80,108,000	$	8,133,000	$	6,866,000		$	211,429,000

	On July 31, 2013, we performed impairment studies of the Company’s goodwill and indefinite lived trademarks and trade names and concluded that such assets were not impaired. While the results of these annual reviews have historically not indicated impairment, impairment reviews are highly dependent on management’s projections of our future operating results and cash flows (which management believes to be reasonable), discount rates based on the Company’s weighted average cost of capital and appropriate benchmark peer companies. Assumptions used in determining future operating results and cash flows include current and expected market conditions and future sales forecasts. Subsequent changes in these assumptions and estimates could result in future impairment. Although we consistently use the same methods in developing the assumptions and estimates underlying the fair value calculations, such estimates are uncertain by nature and can vary from actual results. At July 31, 2013, the average fair value of all of our reporting units exceeded book value by substantial amounts, except our Specialty Packaging segment, which had an average estimated fair value that approximated book value. At October 31, 2013, goodwill relating to our Specialty Packaging reporting unit was $6,866,000. We believe the most significant assumptions impacting the impairment assessment of Specialty Packaging relate to an assumed compounded annual sales growth of 10.7% and future operating efficiencies included in our projections of future operating results and cash flows of this segment, which projections are in excess of historical run rates. If future operating results and cash flows are substantially less than our projections, future impairment charges may be recorded. On October 31, 2013, management concluded that no events or changes in circumstances have occurred during the three months ended October 31, 2013 that would indicate that the carrying amount of our intangible assets and goodwill may not be recoverable.

Warranties

Warranties	3 Months Ended
	Oct. 31, 2013
Warranties	'
Warranties	'
	Note 8. Warranties

	A summary of activity in the Company’s warranty reserves follows:

		Three Months Ended
		October 31,
		2013			2012

	Beginning balance	$	1,261,000		$	1,667,000
	Provisions	691,000			367,000
	Settlements	(691,000		)	(596,000		)
	Ending balance	$	1,261,000		$	1,438,000

	The warranty provisions and settlements for the three months ended October 31, 2013 and 2012 relate principally to the Company’s endoscope reprocessing and water purification equipment. Warranty reserves are included in accrued expenses in the Condensed Consolidated Balance Sheets.

Financing_Arrangements

Financing Arrangements	3 Months Ended
Financing Arrangements	Oct. 31, 2013
Financing Arrangements	'
Financing Arrangements	'
	Note 9. Financing Arrangements

	We entered into a $150,000,000 Second Amended and Restated Credit Agreement dated as of August 1, 2011 (the “U.S. Credit Agreement”) which includes (i) a five-year $100,000,000 senior secured revolving credit facility with sublimits of up to $20,000,000 for letters of credit and up to $5,000,000 for swing line loans (the “Revolving Credit Facility”) and (ii) a $50,000,000 senior secured term loan facility (the “Term Loan Facility”). The U.S. Credit Agreement expires on August 1, 2016. Amounts we repay under the Term Loan Facility may not be reborrowed. Subject to the satisfaction of certain conditions precedent, the Company may from time to time increase the Revolving Credit Facility by an aggregate amount not to exceed $50,000,000 without the consent of the lenders. The senior lenders include Bank of America (the lead bank and administrative agent), PNC Bank, National Association, and Wells Fargo Bank, National Association. Debt issuance costs relating to the U.S. Credit Agreement were recorded in other assets and are being amortized over the life of the credit facilities. Such unamortized debt issuance costs amounted to $691,000 at October 31, 2013.

	Borrowings under the U.S. Credit Agreement bear interest at rates ranging from 0.25% to 2.00% above the lender’s base rate, or at rates ranging from 1.25% to 3.00% above the London Interbank Offered Rate (“LIBOR”), depending upon the Company’s “Consolidated Leverage Ratio,” which is defined as the consolidated ratio of total funded debt to earnings before interest, taxes, depreciation and amortization, and as further adjusted under the terms of the U.S. Credit Agreement (“Consolidated EBITDA”). At October 31, 2013, the lender’s base rate was 3.25% and the LIBOR rates ranged from 0.17 % to 0.87%. The margins applicable to our outstanding borrowings were 0.75% above the lender’s base rate or 1.75% above LIBOR. Substantially all of our outstanding borrowings were under LIBOR contracts at October 31, 2013. The U.S. Credit Agreement also provides for fees on the unused portion of our facilities at rates ranging from 0.25% to 0.50%, depending upon our Consolidated Leverage Ratio; such rate was 0.30% at October 31, 2013.

	In order to protect our interest rate exposure in future years, we entered into forward starting interest rate swap agreements in February 2012 in which we agree to exchange our variable interest cash flows with fixed interest cash flows provided by one of our existing senior lenders. With respect to our Term Loan Facility, the interest rate swap is for the period that began August 8, 2012 and ends July 31, 2015, initially covering $40,000,000 of borrowings based on one-month LIBOR and thereafter reducing in quarterly $2,500,000 increments consistent with the mandatory repayment schedule, and the fixed interest cash flow is at a one month LIBOR rate of 0.664%. With respect to our Revolving Credit Facility, the interest rate swap is for the period that began August 8, 2012 and ends January 31, 2014, initially covering $25,000,000 of borrowings based on one-month LIBOR and thereafter reducing semi-annually by increments of $5,000,000, and the fixed interest cash flow is at a one month LIBOR rate of 0.496%.

	The principal amounts of the Term Loan Facility are to be paid in twenty consecutive quarterly installments of $2,500,000 beginning on September 30, 2011. The U.S. Credit Agreement permits us to make optional prepayments of loans at any time without premium or penalty other than customary LIBOR breakage fees. We are required to make mandatory prepayments of amounts outstanding under the U.S. Credit Agreement of: (i) 100% of the net proceeds received from certain sales or other dispositions of all or any part of the Company and its subsidiaries’ assets, (ii) 100% of certain insurance and condemnation proceeds received by the Company or any of its subsidiaries, (iii) subject to certain exceptions, 100% of the net cash proceeds received by the Company or any of its subsidiaries from the issuance or occurrence of any indebtedness of the Company or any of its subsidiaries, and (iv) subject to certain exceptions, 100% of the net proceeds of the sale of certain equity.

	The U.S. Credit Agreement contains affirmative and negative covenants reasonably customary for similar credit facilities and is secured by (i) substantially all assets of Cantel and its United States-based subsidiaries (including Medivators, Mar Cor, Crosstex, SPS Medical and Strong Dental Products, Inc.) and (ii) a pledge by Cantel of all of the outstanding shares of Medivators, Mar Cor, Crosstex, SPS Medical and Strong Dental owned by Cantel and 65% of the outstanding shares of Cantel’s foreign-based subsidiaries. We are in compliance with all financial and other covenants under the U.S. Credit Agreement.

	On October 31, 2013, we had $82,000,000 of outstanding borrowings under the U.S. Credit Agreement, which consisted of $27,500,000 and $54,500,000 under the Term Loan Facility and the Revolving Credit Facility, respectively, and $45,500,000 was available to be borrowed under our Revolving Credit Facility. Subsequent to October 31, 2013, we repaid $2,500,000 under our Revolving Credit Facility resulting in total outstanding borrowings of $79,500,000 at November 29, 2013.

Earnings_Per_Common_Share

Earnings Per Common Share	3 Months Ended
Earnings Per Common Share	Oct. 31, 2013
Earnings Per Common Share	'
Earnings Per Common Share	'
	Note 10. Earnings Per Common Share

	Basic EPS is computed based upon the weighted average number of common shares outstanding during the period. Diluted EPS is computed based upon the weighted average number of common shares outstanding during the period plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the period.

	We include participating securities (unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents) in the computation of EPS pursuant to the two-class method. Our participating securities consist solely of unvested restricted stock awards, which have contractual participation rights equivalent to those of stockholders of unrestricted common stock. The two-class method of computing earnings per share is an allocation method that calculates earnings per share for common stock and participating securities.

	The following table sets forth the computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities):

		Three Months Ended
		October 31,
		2013			2012
	Numerator for basic and diluted earnings per share:
	Net income	$	11,185,000		$	9,576,000
	Less income allocated to participating securities	(160,000		)	(157,000		)
	Net income available to common stockholders	$	11,025,000		$	9,419,000

	Denominator for basic and diluted earnings per share, as adjusted for participating securities:
	Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock	40,582,755			39,997,443

	Dilutive effect of stock options using the treasury stock method and the average market price for the period	192,105			364,238

	Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,774,860			40,361,681

	Earnings per share attributable to common stock:
	Basic earnings per share	$	0.27		$	0.24

	Diluted earnings per share	$	0.27		$	0.23

	Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive	30,000			—

	A reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, as determined above, to the Company’s total weighted average number of shares and common stock equivalents, including participating securities, are set forth in the following table:

		Three Months Ended
		October 31,
		2013		2012
	Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,774,860		40,361,681

	Participating securities	598,209		679,892

	Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities	41,373,069		41,041,573

Income_Taxes

Income Taxes	3 Months Ended
	Oct. 31, 2013
Income Taxes	'
Income Taxes	'
	Note 11. Income Taxes

	The consolidated effective tax rate was 36.7% and 37.6% for the three months ended October 31, 2013 and 2012, respectively. The decrease in the consolidated effective tax rate was principally due to the geographic mix of pre-tax income and the impact of Federal tax legislation re-enacted in January 2013, as described below.

	For the three months ended October 31, 2013 and 2012, approximately 96% and 98%, respectively, of our income before income taxes was generated from our United States operations, which had an overall effective tax rate of 37.3% and 37.9%, respectively. The lower overall effective tax rate for the three months ended October 31, 2013 was principally caused by Federal tax legislation that had expired in December 2011, but was re-enacted retroactively in January 2013, that enabled us to record the research and experimentation tax credit in the current period. Due to the timing of the expiration and re-enactment of this legislation, the research and experimentation tax credit was not recorded during the three months ended October 31, 2012.

	For the three months ended October 31, 2013 and 2012, approximately 4% and 2%, respectively, of our income before income taxes was generated from our operations in Canada, Singapore and the Netherlands. Collectively, these operations had an overall effective tax rate of 23.0% and 21.5% for the three months ended October 31, 2013 and 2012, respectively. All three of these locations have lower statutory income tax rates compared to the United States.

	We record liabilities for an unrecognized tax benefit when a tax benefit for an uncertain tax position is taken or expected to be taken on a tax return, but is not recognized in our Condensed Consolidated Financial Statements because it does not meet the more-likely-than-not recognition threshold that the uncertain tax position would be sustained upon examination by the applicable taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon settlement with the tax authorities. Any adjustments upon resolution of income tax uncertainties are recognized in our results of operations. However, if our unrecognized tax benefits are recognized in our financial statements in future periods, there would not be a significant impact to our overall effective tax rate due to the size of the unrecognized tax benefits in relation to our income before income taxes. We do not expect such unrecognized tax benefits to significantly decrease or increase in the next twelve months.

	A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits is as follows:

		Unrecognized
		Tax Benefits

	Unrecognized tax benefits on July 31, 2012	$	124,000
	Activity during fiscal 2013	—
	Unrecognized tax benefits on July 31, 2013	124,000
	Activity during the three months ended October 31, 2013	—
	Unrecognized tax benefits on October 31, 2013	$	124,000

	Generally, the Company is no longer subject to federal, state or foreign income tax examinations for fiscal years ended prior to July 31, 2005.

	Our policy is to record potential interest and penalties related to income tax positions in interest expense and general and administrative expense, respectively, in our Condensed Consolidated Financial Statements. However, such amounts have been relatively insignificant due to the amount of our unrecognized tax benefits relating to uncertain tax positions.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Oct. 31, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	Note 12. Commitments and Contingencies

	Long-Term Contractual Obligations

	As of October 31, 2013, aggregate annual required payments over the remaining fiscal year, the next four years and thereafter under our contractual obligations that have long-term components were as follows:

		Nine Months
		Ending
		July 31,		Year Ending July 31,
		2014		2015		2016		2017		2018		Thereafter		Total
		(Amounts in thousands)
	Maturities of the credit facilities	$	7,500	$	10,000	$	10,000	$	54,500	$	—	$	—	$	82,000
	Expected interest payments under the credit facilities (1)	1,439		1,707		1,466		4		—		—		4,616
	Minimum commitments under noncancelable operating leases	2,748		2,892		1,996		1,370		1,163		3,654		13,823
	Compensation agreements	3,223		2,478		494		75		—		—		6,270
	Deferred compensation and other	41		55		43		42		36		27		244
	Total contractual obligations	$	14,951	$	17,132	$	13,999	$	55,991	$	1,199	$	3,681	$	106,953

	(1) The expected interest payments under both the term and revolving credit facilities reflect interest rates of 2.41% and 2.45%, which were our weighted average interest rates on outstanding borrowings at October 31, 2013 and reflect the impact of our interest rate swap agreements.

	Operating Leases

	Minimum commitments under operating leases include minimum rental commitments for our leased manufacturing facilities, warehouses, office space and equipment.

	Compensation Agreements

	We have previously entered into various severance contracts with executives of the Company, including our Corporate executive officers and our subsidiary Chief Executive Officers, which define certain compensation arrangements relating to various employment termination scenarios. In conjunction with the acquisitions of the Byrne Medical Business on August 1, 2011, the SPS Business on November 1, 2012 and the Eagle Pure Water Business on December 31, 2012, we entered into three-year employment agreements with certain executive officers of the acquired businesses.

	Deferred Compensation and Other

	Deferred compensation and other primarily includes deferred compensation arrangements for certain former Medivators directors and officers and is recorded in other long-term liabilities.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Oct. 31, 2013
Accumulated Other Comprehensive Income (Loss)	'
Accumulated Other Comprehensive Income (Loss)	'
	Note 13. Accumulated Other Comprehensive Income (Loss)

	The components and changes in accumulated other comprehensive income (loss) for the three months ended October 31, 2013 and 2012 were as follows:

		Three Months Ended
		October 31, 2013
		Foreign
		Currency			Interest Rate
		Translation			Swap
		Adjustments			Agreements			Total

	Beginning balance	$	11,080,000		$	(103,000	)	$	10,977,000
	Other comprehensive loss before reclassifications	(273,000		)	(33,000		)	(306,000		)
	Income tax effect on other comprehensive loss before reclassification	—			12,000			12,000
	Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	—			48,000			48,000
	Income tax effect on reclassification adjustments	—			(18,000		)	(18,000		)
	Ending balance	$	10,807,000		$	(94,000	)	$	10,713,000

		Three Months Ended
		October 31, 2012
		Foreign
		Currency			Interest Rate
		Translation			Swap
		Adjustments			Agreements			Total

	Beginning balance	$	8,385,000		$	(210,000	)	$	8,175,000
	Other comprehensive income (loss) before reclassifications	122,000			(18,000		)	104,000
	Income tax effect on other comprehensive income (loss) before reclassification	(31,000		)	7,000			(24,000		)
	Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	—			55,000			55,000
	Income tax effect on reclassification adjustments	—			(21,000		)	(21,000		)
	Ending balance	$	8,476,000		$	(187,000	)	$	8,289,000

Operating_Segments

Operating Segments	3 Months Ended
	Oct. 31, 2013
Operating Segments	'
Operating Segments	'
	Note 14. Operating Segments

	Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products.

	In accordance with FASB ASC Topic 280, “Segment Reporting,” (“ASC 280”), we have determined our reportable business segments based upon an assessment of product types, organizational structure, customers and internally prepared financial statements. The primary factors used by us in analyzing segment performance are net sales and operating income.

	During the fourth quarter of fiscal 2013, we changed our internal reporting processes by combining our Therapeutic Filtration and Chemistries operating segments, previously reported in the Other reporting segment, with our Water Purification and Filtration reporting segment to reflect the way the Company, through its executive management, manages, allocates resources and measures the performance of its businesses. All periods presented have been recast to reflect these changes.

	None of our customers accounted for 10% or more of our consolidated net sales for the three months ended October 31, 2013 and 2012, except for DaVita Inc. (“DaVita”), which accounted for approximately 10.1%, or approximately $11,988,000, for the three months ended October 31, 2013 and approximately 10.4%, or $10,360,000, for the three months ended October 31, 2012, of our consolidated net sales. For the three months ended October 31, 2013, DaVita accounted for approximately 23.1% and 38.5% of our net sales in our Water Purification and Filtration and Dialysis segments, respectively.

	The Company’s segments are as follows:

	Endoscopy, which includes medical device reprocessing systems, disinfectants, detergents and other supplies used to high-level disinfect flexible endoscopes. This segment also offers disposable infection control products intended to eliminate the challenges associated with proper cleaning and high-level disinfection of numerous reusable components used in gastrointestinal (GI) endoscopy procedures. Additionally, this segment includes technical maintenance service on its products.

	Water Purification and Filtration, which includes water purification equipment design and manufacturing, project management, installation, maintenance, deionization and mixing systems, as well as hollow fiber membrane filtration and separation technologies for high-purity fluid and separation applications for healthcare (with a large concentration in dialysis), pharmaceutical, biotechnology, research, beverage, semiconductor and other commercial industries. Additionally, this segment includes sterilants, disinfectants and decontamination services used in various applications for infection prevention and control.

	DaVita and another large customer accounted for approximately 23.1% and 23.8%, respectively, of our Water Purification and Filtration segment net sales for the three months ended October 31, 2013. Combined, these two customers accounted for approximately 18.1% of our consolidated net sales for the three months ended October 31, 2013.

	Healthcare Disposables, which includes single-use infection prevention and control products used principally in the dental market such as face masks, sterilization pouches, patient towels and bibs, self-sealing sterilization pouches, tray covers, surface barriers including eyewear, aprons and gowns, disinfectants, germicidal wipes, hand care products, gloves, sponges, cotton products, cups, needles and syringes, scalpels and blades, and saliva evacuators and ejectors. This segment also manufactures and provides biological and chemical indicators for sterility assurance monitoring services in the acute-care, alternate-care and dental markets.

	Four customers collectively accounted for approximately 55.6% of our Healthcare Disposables segment net sales and approximately 12.3% of our consolidated net sales for the three months ended October 31, 2013.

	Dialysis, which includes disinfection/sterilization reprocessing equipment, sterilants, supplies and concentrates related to hemodialysis treatment of patients with acute kidney failure or chronic kidney failure associated with end-stage renal disease. Additionally, this segment includes technical maintenance service on its products.

	Other

	In accordance with quantitative thresholds established by ASC 280, the Specialty Packaging operating segment is reported in the Other reporting segment.

	Specialty Packaging, which includes specialty packaging and thermal control products, as well as related compliance training, for the safe transport of infectious and biological specimens and thermally sensitive pharmaceutical, medical and other products.

	The operating segments follow the same accounting policies used for our Condensed Consolidated Financial Statements as described in Note 2 to the 2013 Form 10-K.

	Information as to operating segments is summarized below:

		Three Months Ended
		October 31,
		2013			2012

	Net sales:
	Endoscopy	$	43,613,000		$	36,679,000
	Water Purification and Filtration	39,750,000			33,161,000
	Healthcare Disposables	26,249,000			19,955,000
	Dialysis	7,309,000			8,187,000
	Other	1,351,000			1,699,000
	Total	$	118,272,000		$	99,681,000

	Operating income:
	Endoscopy	$	8,184,000		$	7,676,000
	Water Purification and Filtration	6,057,000			4,627,000
	Healthcare Disposables	5,719,000			4,091,000
	Dialysis	1,764,000			2,176,000
	Other	5,000			213,000
		21,729,000			18,783,000
	General corporate expenses	(3,417,000		)	(2,811,000		)
	Interest expense, net	(644,000		)	(633,000		)

	Income before income taxes	$	17,668,000		$	15,339,000

Legal_Proceedings

Legal Proceedings	3 Months Ended
Legal Proceedings	Oct. 31, 2013
Legal Proceedings	'
Legal Proceedings	'
	Note 15. Legal Proceedings

	In the normal course of business, we are subject to pending and threatened legal actions. It is our policy to accrue for amounts related to these legal matters if it is probable that a liability has been incurred and an amount of anticipated exposure can be reasonably estimated. We do not believe that any of these pending claims or legal actions will have a material effect on our business, financial condition, results of operations or cash flows.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Oct. 31, 2013
Stock-Based Compensation	'
Schedule of the income statement components of stock-based compensation expense recognized in the Condensed Consolidated Statements of Income	'

		Three Months Ended
		October 31,
		2013			2012

	Cost of sales	$	62,000		$	55,000
	Operating expenses:
	Selling	110,000			99,000
	General and administrative	964,000			792,000
	Research and development	12,000			12,000
	Total operating expenses	1,086,000			903,000
	Stock-based compensation before income taxes	1,148,000			958,000
	Income tax benefits	(412,000		)	(340,000		)
	Total stock-based compensation expense, net of tax	$	736,000		$	618,000
Summary of nonvested stock award activity	'
				Weighted
		Number of		Average
		Shares		Fair Value

	Nonvested stock awards at July 31, 2013	605,767		$	11.96
	Granted	246,136		31.82
	Canceled	(1,998	)	9.02
	Vested	(286,215	)	10.31
	Nonvested stock awards at October 31, 2013	563,690		$	21.48
Weighted-average assumptions used to estimate fair value of stock options granted using the Black-Scholes option valuation model	'

	Weighted-Average
	Black-Scholes Option	Three Months Ended		Three Months Ended
	Valuation Assumptions	October 31, 2013		October 31, 2012

	Dividend yield	0.28	%	0.37	%
	Expected volatility (1)	42.7	%	50.9	%
	Risk-free interest rate (2)	1.44	%	0.67	%
	Expected lives (in years) (3)	5		5

	(1) Volatility was based on historical closing prices of our common stock.
	(2) The U.S. Treasury rate on the expected life at the date of grant.
	(3) Based on historical exercise behavior.
Summary of stock option activity	'
				Weighted
		Number of		Average
		Shares		Exercise Price

	Outstanding at July 31, 2013	403,831		$	8.25
	Granted	30,000		31.81
	Exercised	(27,002	)	6.01
	Outstanding at October 31, 2013	406,829		$	10.14

	Exercisable at July 31, 2013	351,331		$	6.94

	Exercisable at October 31, 2013	341,829		$	7.53

Acquisitions_Tables

Acquisitions (Tables)	3 Months Ended
Acquisitions (Tables)	Oct. 31, 2013
Siemens' Hemodialysis Water Business	'
Acquisitions	'
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	'

		Final
	Net Assets	Allocation
	Current assets	$	728,000
	Property, plant and equipment	231,000
	Amortizable intangible assets:
	Customer relationships (12- year life)	4,310,000
	Current liabilities	(415,000		)
	Net assets acquired	$	4,854,000
Eagle Pure Water Systems, Inc.	'
Acquisitions	'
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	'
		Final
	Net Assets	Allocation
	Current assets	$	8,000
	Property, plant and equipment	70,000
	Amortizable intangible assets (3- year weighted average life):
	Customer relationships (3- year life)	150,000
	Brand names (3- year life)	18,000
	Non-compete agreement (5- year life)	32,000
	Current liabilities	(5,000		)
	Net assets acquired	$	273,000
SPS Medical Supply Corp	'
Acquisitions	'
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	'

		Final
	Net Assets	Allocation
	Current assets	$	4,810,000
	Property, plant and equipment	3,801,000
	Amortizable intangible assets (9- year weighted average life):
	Customer relationships (10- year life)	8,120,000
	Brand names (5- year life)	760,000
	Technology (4- year life)	500,000
	Non-compete agreements (6- year life)	180,000
	Other assets	28,000
	Current liabilities	(2,784,000		)
	Noncurrent deferred income tax liabilities, net	(3,659,000		)
	Net assets acquired	$	11,756,000

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Oct. 31, 2013
Fair Value Measurements	'
Schedule of fair values of financial instruments measured on a recurring basis	'

		October 31, 2013
		Level 1			Level 2			Level 3			Total
	Assets:
	Cash and cash equivalents:
	Money markets	$	4,571,000		$	—		$	—		$	4,571,000
	Total assets	$	4,571,000		$	—		$	—		$	4,571,000

	Liabilities:
	Accrued expenses:
	Interest rate swap agreements	$	—		$	112,000		$	—		$	112,000
	Price floor	—			—			1,000			1,000
	Total accrued expenses	—			112,000			1,000			113,000
	Other long-term liabilities:
	Interest rate swap agreements	—			35,000			—			35,000
	Total liabilities	$	—		$	147,000		$	1,000		$	148,000

		July 31, 2013
		Level 1			Level 2			Level 3			Total
	Assets:
	Cash and cash equivalents:
	Money markets	$	4,241,000		$	—		$	—		$	4,241,000
	Total assets	$	4,241,000		$	—		$	—		$	4,241,000

	Liabilities:
	Accrued expenses:
	Interest rate swap agreements	$	—		$	133,000		$	—		$	133,000
	Total accrued expenses	—			133,000			—			133,000
	Other long-term liabilities:
	Price floor	—			—			45,000			45,000
	Interest rate swap agreements	—			29,000			—			29,000
	Total other long-term liabilities	—			29,000			45,000			74,000
	Total liabilities	$	—		$	162,000		$	45,000		$	207,000
Reconciliation of liabilities measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3)	'
		Byrne			Byrne
		Contingent			Price
		Consideration			Floor			Total
	Balance, July 31, 2012	$	1,500,000		$	1,037,000		$	2,537,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(313,000		)	(313,000		)
	Transfers into or out of level 3	—			—			—
	Net purchases, issuances, sales and settlements	—			—			—
	Balance, October 31, 2012	1,500,000			724,000			2,224,000
	Total net unrealized gains included in general and administrative expense in earnings	(1,500,000		)	(410,000		)	(1,910,000		)
	Transfers into or out of level 3	—			—			—
	Net purchases, issuances, sales and settlements	—			—			—
	Balance, January 31, 2013	—			314,000			314,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(59,000		)	(59,000		)
	Transfers into or out of level 3	—			—			—
	Net purchases, issuances, sales and settlements	—			—			—
	Balance, April 30, 2013	—			255,000			255,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(210,000		)	(210,000		)
	Transfers into or out of level 3	—			—			—
	Net purchases, issuances, sales and settlements	—			—			—
	Balance, July 31, 2013	—			45,000			45,000
	Total net unrealized gains included in general and administrative expense in earnings	—			(44,000		)	(44,000		)
	Transfers into or out of level 3	—			—			—
	Net purchases, issuances, sales and settlements	—			—			—
	Balance, October 31, 2013	$	—		$	1,000		$	1,000

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	3 Months Ended
Intangible Assets and Goodwill (Tables)	Oct. 31, 2013
Intangible Assets and Goodwill	'
Schedule of intangible assets	'

		October 31, 2013
				Accumulated
		Gross		Amortization			Net
	Intangible assets with finite lives:
	Customer relationships	$	71,846,000	$	(26,483,000	)	$	45,363,000
	Technology	20,509,000		(9,730,000		)	10,779,000
	Brand names	12,680,000		(8,392,000		)	4,288,000
	Non-compete agreements	3,159,000		(603,000		)	2,556,000
	Patents and other registrations	1,820,000		(653,000		)	1,167,000
		110,014,000		(45,861,000		)	64,153,000
	Trademarks and trade names	9,359,000		—			9,359,000
	Total intangible assets	$	119,373,000	$	(45,861,000	)	$	73,512,000

		July 31, 2013
				Accumulated
		Gross		Amortization			Net
	Intangible assets with finite lives:
	Customer relationships	$	72,142,000	$	(25,379,000	)	$	46,763,000
	Technology	21,006,000		(9,642,000		)	11,364,000
	Brand names	12,680,000		(8,045,000		)	4,635,000
	Non-compete agreements	3,159,000		(541,000		)	2,618,000
	Patents and other registrations	1,768,000		(606,000		)	1,162,000
		110,755,000		(44,213,000		)	66,542,000
	Trademarks and trade names	9,387,000		—			9,387,000
	Total intangible assets	$	120,142,000	$	(44,213,000	)	$	75,929,000
Schedule of estimated annual amortization expense of intangible assets for remainder of fiscal 2014 and the next five years	'

	Nine month period ending July 31, 2014	$	7,856,000
	Fiscal 2015	10,229,000
	Fiscal 2016	6,989,000
	Fiscal 2017	6,413,000
	Fiscal 2018	6,136,000
	Fiscal 2019	5,813,000
Schedule of changes in goodwill	'

				Water
				Purification			Healthcare							Total
		Endoscopy		and Filtration			Disposables		Dialysis		Other			Goodwill

	Balance, July 31, 2012	$	59,230,000	$	53,288,000		$	55,864,000	$	8,133,000	$	7,140,000		$	183,655,000
	Acquisitions	—		4,043,000			24,244,000		—		—			28,287,000
	Foreign currency translation	—		(152,000		)	—		—		(172,000		)	(324,000		)
	Balance, July 31, 2013	59,230,000		57,179,000			80,108,000		8,133,000		6,968,000			211,618,000
	Foreign currency translation	—		(87,000		)	—		—		(102,000		)	(189,000		)
	Balance, October 31, 2013	$	59,230,000	$	57,092,000		$	80,108,000	$	8,133,000	$	6,866,000		$	211,429,000

Warranties_Tables

Warranties (Tables)	3 Months Ended
	Oct. 31, 2013
Warranties	'
Summary of activity in warranty reserves	'

		Three Months Ended
		October 31,
		2013			2012

	Beginning balance	$	1,261,000		$	1,667,000
	Provisions	691,000			367,000
	Settlements	(691,000		)	(596,000		)
	Ending balance	$	1,261,000		$	1,438,000

Earnings_Per_Common_Share_Tabl

Earnings Per Common Share (Tables)	3 Months Ended
Earnings Per Common Share (Tables)	Oct. 31, 2013
Earnings Per Common Share	'
Schedule of computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities)	'

		Three Months Ended
		October 31,
		2013			2012
	Numerator for basic and diluted earnings per share:
	Net income	$	11,185,000		$	9,576,000
	Less income allocated to participating securities	(160,000		)	(157,000		)
	Net income available to common stockholders	$	11,025,000		$	9,419,000

	Denominator for basic and diluted earnings per share, as adjusted for participating securities:
	Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock	40,582,755			39,997,443

	Dilutive effect of stock options using the treasury stock method and the average market price for the period	192,105			364,238

	Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,774,860			40,361,681

	Earnings per share attributable to common stock:
	Basic earnings per share	$	0.27		$	0.24

	Diluted earnings per share	$	0.27		$	0.23

	Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive	30,000			—
Schedule of reconciliation of weighted average number of shares and common stock equivalents attributable to common stock to the Company's total weighted average number of shares and common stock equivalents including participating securities	'

		Three Months Ended
		October 31,
		2013		2012
	Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,774,860		40,361,681

	Participating securities	598,209		679,892

	Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities	41,373,069		41,041,573

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Oct. 31, 2013
Income Taxes	'
Schedule of reconciliation of the beginning and ending amounts of gross unrecognized tax benefits	'

		Unrecognized
		Tax Benefits

	Unrecognized tax benefits on July 31, 2012	$	124,000
	Activity during fiscal 2013	—
	Unrecognized tax benefits on July 31, 2013	124,000
	Activity during the three months ended October 31, 2013	—
	Unrecognized tax benefits on October 31, 2013	$	124,000

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Oct. 31, 2013
Commitments and Contingencies	'
Schedule of aggregate annual required payments over the remaining fiscal year, the next four years and thereafter under contractual obligations that have long-term components	'

		Nine Months
		Ending
		July 31,		Year Ending July 31,
		2014		2015		2016		2017		2018		Thereafter		Total
		(Amounts in thousands)
	Maturities of the credit facilities	$	7,500	$	10,000	$	10,000	$	54,500	$	—	$	—	$	82,000
	Expected interest payments under the credit facilities (1)	1,439		1,707		1,466		4		—		—		4,616
	Minimum commitments under noncancelable operating leases	2,748		2,892		1,996		1,370		1,163		3,654		13,823
	Compensation agreements	3,223		2,478		494		75		—		—		6,270
	Deferred compensation and other	41		55		43		42		36		27		244
	Total contractual obligations	$	14,951	$	17,132	$	13,999	$	55,991	$	1,199	$	3,681	$	106,953

	(1) The expected interest payments under both the term and revolving credit facilities reflect interest rates of 2.41% and 2.45%, which were our weighted average interest rates on outstanding borrowings at October 31, 2013 and reflect the impact of our interest rate swap agreements.

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Oct. 31, 2013
Accumulated Other Comprehensive Income (Loss)	'
Schedule of the components and changes in accumulated other comprehensive income (loss)	'

		Three Months Ended
		October 31, 2013
		Foreign
		Currency			Interest Rate
		Translation			Swap
		Adjustments			Agreements			Total

	Beginning balance	$	11,080,000		$	(103,000	)	$	10,977,000
	Other comprehensive loss before reclassifications	(273,000		)	(33,000		)	(306,000		)
	Income tax effect on other comprehensive loss before reclassification	—			12,000			12,000
	Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	—			48,000			48,000
	Income tax effect on reclassification adjustments	—			(18,000		)	(18,000		)
	Ending balance	$	10,807,000		$	(94,000	)	$	10,713,000

		Three Months Ended
		October 31, 2012
		Foreign
		Currency			Interest Rate
		Translation			Swap
		Adjustments			Agreements			Total

	Beginning balance	$	8,385,000		$	(210,000	)	$	8,175,000
	Other comprehensive income (loss) before reclassifications	122,000			(18,000		)	104,000
	Income tax effect on other comprehensive income (loss) before reclassification	(31,000		)	7,000			(24,000		)
	Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	—			55,000			55,000
	Income tax effect on reclassification adjustments	—			(21,000		)	(21,000		)
	Ending balance	$	8,476,000		$	(187,000	)	$	8,289,000

Operating_Segments_Tables

Operating Segments (Tables)	3 Months Ended
Operating Segments (Tables)	Oct. 31, 2013
Operating Segments	'
Information as to operating segments	'

		Three Months Ended
		October 31,
		2013			2012

	Net sales:
	Endoscopy	$	43,613,000		$	36,679,000
	Water Purification and Filtration	39,750,000			33,161,000
	Healthcare Disposables	26,249,000			19,955,000
	Dialysis	7,309,000			8,187,000
	Other	1,351,000			1,699,000
	Total	$	118,272,000		$	99,681,000

	Operating income:
	Endoscopy	$	8,184,000		$	7,676,000
	Water Purification and Filtration	6,057,000			4,627,000
	Healthcare Disposables	5,719,000			4,091,000
	Dialysis	1,764,000			2,176,000
	Other	5,000			213,000
		21,729,000			18,783,000
	General corporate expenses	(3,417,000		)	(2,811,000		)
	Interest expense, net	(644,000		)	(633,000		)

	Income before income taxes	$	17,668,000		$	15,339,000

Basis_of_Presentation_Details

Basis of Presentation (Details)	3 Months Ended	12 Months Ended
	Oct. 31, 2013	Jul. 31, 2013
	item	item
Basis of Presentation	'	'
Number of principal operating companies	5	5
Business Description	'	'
Number of operating segments	5	'
Additional common stock issued as stock dividend (in shares)	'	15,044,000
Stock split ratio	'	1.5
Percentage of stock dividend paid	'	50.00%
Medivators	'	'
Business Description	'	'
Number of foreign subsidiaries	2	'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
Stock-Based Compensation (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'
Stock-based compensation before income taxes	$1,148,000	$958,000
Income tax benefits	-412,000	-340,000
Total stock-based compensation expense, net of tax	736,000	618,000
Cost of sales	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'
Stock-based compensation before income taxes	62,000	55,000
Operating expenses: Selling	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'
Stock-based compensation before income taxes	110,000	99,000
Operating expenses: General and administrative	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'
Stock-based compensation before income taxes	964,000	792,000
Operating expenses: Research and development	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'
Stock-based compensation before income taxes	12,000	12,000
Total operating expenses	'	'
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income	'	'
Stock-based compensation before income taxes	$1,086,000	$903,000

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	3 Months Ended
Stock-Based Compensation (Details 2) (USD $)	Oct. 31, 2013	Oct. 31, 2012	Jul. 31, 2013
Stock-Based Compensation	'	'	'
Total unrecognized stock-based compensation expense, before income taxes, related to total nonvested stock options and stock awards (in dollars)	$11,580,000	'	'
Remaining weighted average period over which unrecognized stock-based compensation expense is expected to be recognized	'25 months	'	'
Stock-based awards, additional disclosure	'	'	'
Reissued shares from treasury stock for exercise of stock options and grant of stock awards (in shares)	'	127,525	'
Deduction in income tax due to exercise of options and vesting of restricted stock (in dollars)	3,680,000	1,728,000	'
Increase in additional paid-in capital due to excess tax benefit on stock-based compensation expense (in dollars)	2,596,000	913,000	'
Restricted shares	'	'	'
Number of Shares	'	'	'
Nonvested stock awards at the beginning of the period (in shares)	605,767	'	'
Granted (in shares)	246,136	'	'
Cancelled (in shares)	-1,998	'	'
Vested (in shares)	-286,215	'	'
Nonvested stock awards at the end of the period (in shares)	563,690	'	'
Weighted Average Fair Value	'	'	'
Nonvested stock awards at the beginning of the period (in dollars per share)	$11.96	'	'
Granted (in dollars per share)	$31.82	'	'
Cancelled (in dollars per share)	$9.02	'	'
Vested (in dollars per share)	$10.31	'	'
Nonvested stock awards at the end of the period (in dollars per share)	$21.48	'	'
Stock options	'	'	'
Weighted-Average Black-Scholes Option Valuation Assumptions	'	'	'
Dividend yield (as a percent)	0.28%	0.37%	'
Expected volatility (as a percent)	42.70%	50.90%	'
Risk-free interest rate (as a percent)	1.44%	0.67%	'
Expected lives	'5 years	'5 years	'
Stock options, additional disclosure	'	'	'
Weighted average fair value of all options granted (in dollars per share)	$12.08	$7.27	'
Aggregate intrinsic value of all options exercised (in dollars)	$671,000	$264,000	'
Number of Shares	'	'	'
Outstanding at the beginning of the period (in shares)	403,831	'	'
Options granted (in shares)	30,000	52,500	'
Exercised (in shares)	-27,002	'	'
Outstanding at the end of the period (in shares)	406,829	'	'
Exercisable at the end of the period (in shares)	341,829	'	351,331
Weighted Average Exercise Price	'	'	'
Outstanding at the beginning of the period (in dollars per share)	$8.25	'	'
Granted (in dollars per share)	$31.81	'	'
Exercised (in dollars per share)	$6.01	'	'
Outstanding at the end of the period (in dollars per share)	$10.14	'	'
Exercisable at the end of the period (in dollars per share)	$7.53	'	$6.94

Acquisitions_Details

Acquisitions (Details) (Jet Prep Ltd., Medivators, USD $)	0 Months Ended
Acquisitions (Details) (Jet Prep Ltd., Medivators, USD $)	Nov. 05, 2013
Jet Prep Ltd. \| Medivators	'
Acquisitions	'
Total consideration for the transaction, excluding transaction costs	$5,350,000
Period of sales percentage above a minimum threshold over which contingent consideration is based	'7 years

Acquisitions_Details_2

Acquisitions (Details 2) (Siemens' Hemodialysis Water Business, Mar Cor subsidiary, USD $)	0 Months Ended
	Mar. 22, 2013
	item
Acquisitions	'
Transaction costs	$362,000
Total consideration for the transaction, excluding transaction costs	8,300,000
Purchase price allocation to the assets acquired and assumed liabilities based on estimated fair values	'
Current assets	728,000
Property, plant and equipment	231,000
Current liabilities	-415,000
Net assets acquired	4,854,000
Number of in-process research and development projects acquired	0
Goodwill deductible for income tax purposes	3,446,000
Customer relationships	'
Purchase price allocation to the assets acquired and assumed liabilities based on estimated fair values	'
Amortizable intangible assets	4,310,000
Amortizable intangible assets, useful life	'12 years
Minimum	'
Acquisitions	'
Number of dialysis customers	600
Revenues generated by acquiree in latest fiscal year before the business acquisition	$9,000,000

Acquisitions_Details_3

Acquisitions (Details 3) (Eagle Pure Water Systems, Inc., USD $)	0 Months Ended
	Dec. 31, 2012
	item
Acquisitions	'
Revenues generated by acquiree in latest fiscal year before the business acquisition	$500,000
Consideration for the transaction	870,000
Net Assets	'
Current assets	8,000
Property, plant and equipment	70,000
Current liabilities	-5,000
Net assets acquired	273,000
Amortizable intangible assets, useful life	'3 years
Number of in-process research and development projects acquired	0
Goodwill deductible for income tax purposes	597,000
Customer relationships	'
Net Assets	'
Amortizable intangible assets	150,000
Amortizable intangible assets, useful life	'3 years
Brand name	'
Net Assets	'
Amortizable intangible assets	18,000
Amortizable intangible assets, useful life	'3 years
Non-compete agreement	'
Net Assets	'
Amortizable intangible assets	$32,000
Amortizable intangible assets, useful life	'5 years

Acquisitions_Details_4

Acquisitions (Details 4) (Polyp Trap, USD $)	Nov. 13, 2012
Polyp Trap	'
Acquisitions	'
Consideration for the transaction	$486,000

Acquisitions_Details_5

Acquisitions (Details 5) (Crosstex subsidiary, USD $)	0 Months Ended
	Nov. 03, 2012
	item
SPS Medical Supply Corp. and SPS manufacturing and warehouse facility	'
Net Assets	'
Current assets	$4,810,000
Property, plant and equipment	3,801,000
Other assets, Noncurrent	28,000
Current liabilities	-2,784,000
Noncurrent deferred income tax liabilities, net	-3,659,000
Net assets acquired	11,756,000
Amortizable intangible assets, useful life	'9 years
Number of in-process research and development projects acquired	0
Goodwill	24,244,000
SPS Medical Supply Corp. and SPS manufacturing and warehouse facility \| Customer relationships	'
Net Assets	'
Amortizable intangible assets	8,120,000
Amortizable intangible assets, useful life	'10 years
SPS Medical Supply Corp. and SPS manufacturing and warehouse facility \| Brand name	'
Net Assets	'
Amortizable intangible assets	760,000
Amortizable intangible assets, useful life	'5 years
SPS Medical Supply Corp. and SPS manufacturing and warehouse facility \| Technology	'
Net Assets	'
Amortizable intangible assets	500,000
Amortizable intangible assets, useful life	'4 years
SPS Medical Supply Corp. and SPS manufacturing and warehouse facility \| Non-compete agreement	'
Net Assets	'
Amortizable intangible assets	180,000
Amortizable intangible assets, useful life	'6 years
SPS Medical Supply Corp	'
Acquisitions	'
Revenues generated by acquiree in latest fiscal year before the business acquisition	17,500,000
Transaction costs	157,000
Total consideration for the transaction, excluding transaction costs	32,500,000
SPS manufacturing and warehouse facility in Rochester, New York	'
Acquisitions	'
Consideration for the transaction	$3,500,000

Derivatives_Details

Derivatives (Details) (USD $)	1 Months Ended	3 Months Ended				3 Months Ended		3 Months Ended		3 Months Ended
	Feb. 29, 2012	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Aug. 08, 2012	Oct. 31, 2013	Aug. 08, 2012	Oct. 31, 2013	Aug. 08, 2012	Oct. 31, 2013	Aug. 08, 2012
	item	Foreign currency forward contracts	Foreign currency forward contracts	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements	Interest rate swap agreements
		Fair value hedge instruments	Fair value hedge instruments	Term Loan Facility	Term Loan Facility	Revolving Credit Facility	Revolving Credit Facility	Cash flow hedge instruments	Cash flow hedge instruments	Cash flow hedge instruments	Cash flow hedge instruments
		item						Term Loan Facility	Term Loan Facility	Revolving Credit Facility	Revolving Credit Facility
Derivatives	'	'	'	'	'	'	'	'	'	'	'
Term of contracts	'	'1 month	'	'	'	'	'	'	'	'	'
Number of contracts	'	2	'	'	'	'	'	'	'	'	'
Aggregate value of contracts	'	$6,381,000	'	'	'	'	'	'	'	'	'
Term of renewed contracts	'	'1 month	'	'	'	'	'	'	'	'	'
Net currency conversion loss, net of tax	'	62,000	15,000	'	'	'	'	'	'	'	'
Number of existing senior lenders of debt, whose variable interest cash flows will be exchanged by the entity with fixed interest cash flows	1	'	'	'	'	'	'	'	'	'	'
Borrowing initially hedged	'	'	'	'	40,000,000	'	25,000,000	'	40,000,000	'	25,000,000
Reference rate, description	'	'	'	'	'	'	'	'one month LIBOR	'	'one month LIBOR	'
Quarterly reduction in borrowings hedged	'	'	'	2,500,000	'	'	'	2,500,000	'	'	'
Semi-annual reduction in borrowings hedged	'	'	'	'	'	$5,000,000	'	'	'	$5,000,000	'
Reference rate (as a percent)	'	'	'	'	'	'	'	0.66%	'	0.50%	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	1 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended
	Feb. 29, 2012	Jul. 31, 2013	Aug. 02, 2011	Nov. 30, 2013	Jul. 29, 2011
	item		Recurring basis	Recurring basis	Recurring basis
			Level 3	Level 3	Level 3
			Byrne Medical Business	Byrne Medical Business	Byrne Medical Business
Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis	'	'	'	'	'
Number of existing senior lenders of debt, whose variable interest cash flows will be exchanged by the entity with fixed interest cash flows	1	'	'	'	'
Initial contingent consideration liability	'	'	$2,700,000	'	'
Initial price floor	'	'	3,000,000	'	'
Price floor period	'	'	'3 years	'	'
Discount rate of cash flow projections (as a percent)	'	'	14.00%	'	'
Contingent consideration period	'	'	'2 years	'	'
Stock split ratio	'	1.5	1.5	'	'
Stock consideration (in shares)	'	'	902,528	'	'
Stock price (in dollars per share)	'	'	$11.08	'	$11.08
Estimated contingent consideration range, high end	'	'	$10,000,000	$6,666,666	'
Cantel common stock placed in escrow at the time of acquisition	'	'	902,528	'	'
Proportion of shares released from escrow	'	'	'	0.33	'
Proportion of estimated contingent consideration reduced as a result of shares released from escrow	'	'	'	0.33	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (Recurring basis, USD $)	Oct. 31, 2013	Jul. 31, 2013
Level 1	'	'
Assets:	'	'
Money markets	$4,571,000	$4,241,000
Total assets	4,571,000	4,241,000
Level 2	'	'
Accrued expenses:	'	'
Interest rate swap agreements	112,000	133,000
Total accrued expenses	112,000	133,000
Other long-term liabilities:	'	'
Interest rate swap agreements	35,000	29,000
Total other long-term liabilities	'	29,000
Total liabilities	147,000	162,000
Level 3	'	'
Accrued expenses:	'	'
Price floor	1,000	'
Total accrued expenses	1,000	'
Other long-term liabilities:	'	'
Price floor	'	45,000
Total other long-term liabilities	'	45,000
Total liabilities	1,000	45,000
Total	'	'
Assets:	'	'
Money markets	4,571,000	4,241,000
Total assets	4,571,000	4,241,000
Accrued expenses:	'	'
Interest rate swap agreements	112,000	133,000
Price floor	1,000	'
Total accrued expenses	113,000	133,000
Other long-term liabilities:	'	'
Price floor	'	45,000
Interest rate swap agreements	35,000	29,000
Total other long-term liabilities	'	74,000
Total liabilities	$148,000	$207,000

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 3) (USD $)	3 Months Ended
	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jan. 31, 2013	Jul. 31, 2012
						Byrne Medical Business	Byrne Medical Business	Byrne Medical Business	Byrne Medical Business	Byrne Medical Business	Contingent consideration liability	Contingent consideration liability
						Three-year price floor	Three-year price floor	Three-year price floor	Three-year price floor	Three-year price floor	Byrne Medical Business	Byrne Medical Business
Reconciliation of liability measured and recorded at fair value on a recurring basis using Level 3	'	'	'	'	'	'	'	'	'	'	'	'
Beginning balance	$45,000	$255,000	$314,000	$2,224,000	$2,537,000	$45,000	$255,000	$314,000	$724,000	$1,037,000	$1,500,000	$1,500,000
Total net unrealized gains included in general and administrative expense in earnings	-44,000	-210,000	-59,000	-1,910,000	-313,000	-44,000	-210,000	-59,000	-410,000	-313,000	-1,500,000	'
Ending balance	$1,000	$45,000	$255,000	$314,000	$2,224,000	$1,000	$45,000	$255,000	$314,000	$724,000	'	$1,500,000

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details 4) (USD $)	3 Months Ended
Fair Value Measurements (Details 4) (USD $)	Oct. 31, 2013
Disclosure of Fair Value of Financial Instruments	'
Impairment of long-lived assets, including goodwill and intangibles with indefinite lives	$0
Minimum	'
Disclosure of Fair Value of Financial Instruments	'
Interest rate base	'One month LIBOR
Maximum	'
Disclosure of Fair Value of Financial Instruments	'
Interest rate base	'Twelve month LIBOR

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill (Details) (USD $)	3 Months Ended
Intangible Assets and Goodwill (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012	Jul. 31, 2013
Intangible assets with finite lives:	'	'	'
Amortization expense	$2,626,000	$2,267,000	'
Gross	110,014,000	'	110,755,000
Accumulated Amortization	-45,861,000	'	-44,213,000
Net	64,153,000	'	66,542,000
Intangible assets with indefinite lives:	'	'	'
Trademarks and trade names	9,359,000	'	9,387,000
Total intangible assets	'	'	'
Gross	119,373,000	'	120,142,000
Accumulated Amortization	-45,861,000	'	-44,213,000
Net	73,512,000	'	75,929,000
Low end of range	'	'	'
Intangible assets with finite lives:	'	'	'
Estimated useful lives	'2 years	'	'
High end of range	'	'	'
Intangible assets with finite lives:	'	'	'
Estimated useful lives	'20 years	'	'
Weighted average	'	'	'
Intangible assets with finite lives:	'	'	'
Estimated useful lives	'11 years	'	'
Customer relationships	'	'	'
Intangible assets with finite lives:	'	'	'
Gross	71,846,000	'	72,142,000
Accumulated Amortization	-26,483,000	'	-25,379,000
Net	45,363,000	'	46,763,000
Total intangible assets	'	'	'
Accumulated Amortization	-26,483,000	'	-25,379,000
Technology	'	'	'
Intangible assets with finite lives:	'	'	'
Gross	20,509,000	'	21,006,000
Accumulated Amortization	-9,730,000	'	-9,642,000
Net	10,779,000	'	11,364,000
Total intangible assets	'	'	'
Accumulated Amortization	-9,730,000	'	-9,642,000
Brand names	'	'	'
Intangible assets with finite lives:	'	'	'
Gross	12,680,000	'	12,680,000
Accumulated Amortization	-8,392,000	'	-8,045,000
Net	4,288,000	'	4,635,000
Total intangible assets	'	'	'
Accumulated Amortization	-8,392,000	'	-8,045,000
Non-compete agreement	'	'	'
Intangible assets with finite lives:	'	'	'
Gross	3,159,000	'	3,159,000
Accumulated Amortization	-603,000	'	-541,000
Net	2,556,000	'	2,618,000
Total intangible assets	'	'	'
Accumulated Amortization	-603,000	'	-541,000
Patents and other registrations	'	'	'
Intangible assets with finite lives:	'	'	'
Gross	1,820,000	'	1,768,000
Accumulated Amortization	-653,000	'	-606,000
Net	1,167,000	'	1,162,000
Total intangible assets	'	'	'
Accumulated Amortization	($653,000)	'	($606,000)

Intangible_Assets_and_Goodwill3

Intangible Assets and Goodwill (Details 2) (USD $)	Oct. 31, 2013
Estimated annual amortization expense of intangible assets for next five years	'
Nine month period ending July 31, 2014	$7,856,000
Fiscal 2015	10,229,000
Fiscal 2016	6,989,000
Fiscal 2017	6,413,000
Fiscal 2018	6,136,000
Fiscal 2019	$5,813,000

Intangible_Assets_and_Goodwill4

Intangible Assets and Goodwill (Details 3) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Jul. 31, 2012

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Jul. 31, 2012

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Endoscopy

Water Purification and Filtration

Healthcare Disposables

Dialysis

Other

Specialty Packaging segment

Changes in Goodwill

Balance at the beginning of the period

$211,618,000

$183,655,000

$59,230,000

$57,179,000

$53,288,000

$55,864,000

$80,108,000

$8,133,000

$6,968,000

$7,140,000

$6,866,000

Acquisitions

28,287,000

4,043,000

24,244,000

Foreign currency translation

-189,000

-324,000

-87,000

-152,000

-102,000

-172,000

Balance at the end of the period

$211,429,000

$211,618,000

$59,230,000

$57,092,000

$57,179,000

$80,108,000

$8,133,000

$6,866,000

$6,968,000

$6,866,000

Assumed compounded annual sales growth impacting the impairment assessments (as a percent)

10.70%

Warranties_Details

Warranties (Details) (USD $)	3 Months Ended
Warranties (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Summary of activity in warranty reserves	'	'
Beginning balance	$1,261,000	$1,667,000
Provisions	691,000	367,000
Settlements	-691,000	-596,000
Ending Balance	$1,261,000	$1,438,000

Financing_Arrangements_Details

Financing Arrangements (Details) (USD $)

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Feb. 29, 2012

Oct. 31, 2013

Nov. 29, 2013

Aug. 02, 2011

Oct. 31, 2013

Aug. 02, 2011

Nov. 29, 2013

Oct. 31, 2013

Aug. 08, 2012

Oct. 31, 2013

Aug. 02, 2011

Oct. 31, 2013

Aug. 08, 2012

Oct. 31, 2013

item

Minimum

Maximum

Lender's base rate

LIBOR

U.S. Credit Agreement

Revolving Credit Facility

Letters of credit

Swing line loans

Term Loan Facility

Minimum

Maximum

Minimum

Maximum

Lender's base rate

LIBOR

Interest rate swap with fixed interest cash flows

One month LIBOR

item

Interest rate swap with fixed interest cash flows

One month LIBOR

Minimum

Maximum

Minimum

Maximum

Interest rate swap with fixed interest cash flows

Financing Arrangements

Maximum borrowing capacity

$150,000,000

$100,000,000

$20,000,000

$5,000,000

Borrowings

50,000,000

Term of line of credit facility

'5 years

Maximum additional borrowing capacity available at the entity's option

50,000,000

Unamortized debt issuance costs

691,000

Margin on reference rate (as a percent)

0.75%

0.25%

2.00%

1.75%

1.25%

3.00%

Reference rate, description

'One month LIBOR

'Twelve month LIBOR

'lender's base rate

'LIBOR

'one month LIBOR

Reference rate (as a percent)

3.25%

0.17%

0.87%

0.50%

0.66%

Fees on unused portion of credit facilities (as a percent)

0.30%

0.25%

0.50%

Number of existing senior lenders of debt, whose variable interest cash flows will be exchanged by the entity with fixed interest cash flows

Borrowing initially hedged

25,000,000

40,000,000

Quarterly reduction in borrowings hedged

2,500,000

Semi-annual reduction in borrowings hedged

5,000,000

Number of quarterly principal installments

Quarterly principal installments

2,500,000

Mandatory prepayments of amounts outstanding as a percentage of net proceeds received from certain sales or other dispositions of all or any part of the entity and its subsidiaries' assets

100.00%

Mandatory prepayments of amounts outstanding as a percentage of certain insurance and condemnation proceeds received by the entity or any of its subsidiaries

100.00%

Mandatory prepayments of amounts outstanding as a percentage of net cash proceeds received from issuance or occurrence of any indebtedness of the entity or any of its subsidiaries

100.00%

Mandatory prepayments of amounts outstanding as a percentage of net proceeds from sale of certain equity

100.00%

Shares of foreign subsidiaries pledged as security (as a percent)

65.00%

Outstanding borrowings

82,000,000

79,500,000

54,500,000

27,500,000

Available borrowing capacity

45,500,000

Repayment of borrowings

$2,500,000

Earnings_Per_Common_Share_Deta

Earnings Per Common Share (Details) (USD $)	3 Months Ended
Earnings Per Common Share (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Numerator for basic and diluted earnings per share:	'	'
Net income	$11,185,000	$9,576,000
Less income allocated to participating securities	-160,000	-157,000
Net income available to common shareholders	$11,025,000	$9,419,000
Denominator for basic and diluted earnings per share, as adjusted for participating securities:	'	'
Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock	40,582,755	39,997,443
Dilutive effect of stock options using the treasury stock method and the average market price for the period (in shares)	192,105	364,238
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,774,860	40,361,681
Basic earnings per share attributable to common stock (in dollars per share)	$0.27	$0.24
Diluted earnings per share attributable to common stock (in dollars per share)	$0.27	$0.23
Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive (in shares)	30,000	'

Earnings_Per_Common_Share_Deta1

Earnings Per Common Share (Details 2)	3 Months Ended
Earnings Per Common Share (Details 2)	Oct. 31, 2013	Oct. 31, 2012
Reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, to the entity's total weighted average number of shares and common stock equivalents, including participating securities	'	'
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock	40,774,860	40,361,681
Participating securities (in shares)	598,209	679,892
Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities	41,373,069	41,041,573

Income_Taxes_Details

Income Taxes (Details)	3 Months Ended
Income Taxes (Details)	Oct. 31, 2013	Oct. 31, 2012
Income Taxes	'	'
Consolidated effective tax rate (as a percent)	36.70%	37.60%
United States	'	'
Income Taxes	'	'
Consolidated effective tax rate (as a percent)	37.30%	37.90%
Percentage of income before income taxes	96.00%	98.00%
Canada, Singapore and Netherlands	'	'
Income Taxes	'	'
Consolidated effective tax rate (as a percent)	23.00%	21.50%
Percentage of income before income taxes	4.00%	2.00%
Number of locations with lower statutory income tax rates compared to the United States	3	'

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Oct. 31, 2013	Jul. 31, 2013	Jul. 31, 2012
Reconciliation of the beginning and ending amounts of gross unrecognized tax benefits	'	'	'
Unrecognized tax benefits at the beginning of the period	$124,000	$124,000	$124,000
Unrecognized tax benefits at the end of the period	$124,000	$124,000	$124,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Oct. 31, 2013
In Thousands, unless otherwise specified	Oct. 31, 2013
Long-Term Contractual Obligations	'
Remaining fiscal year	$14,951
2015	17,132
2016	13,999
2017	55,991
2018	1,199
Thereafter	3,681
Total	106,953
Term Loan Facility	'
Long-Term Contractual Obligations	'
Interest rate (as a percent)	2.41%
Revolving Credit Facility	'
Long-Term Contractual Obligations	'
Interest rate (as a percent)	2.45%
Maturities of the credit facilities	'
Long-Term Contractual Obligations	'
Remaining fiscal year	7,500
2015	10,000
2016	10,000
2017	54,500
Total	82,000
Expected interest payments under the credit facilities	'
Long-Term Contractual Obligations	'
Remaining fiscal year	1,439
2015	1,707
2016	1,466
2017	4
Total	4,616
Minimum commitments under noncancelable operating leases	'
Long-Term Contractual Obligations	'
Remaining fiscal year	2,748
2015	2,892
2016	1,996
2017	1,370
2018	1,163
Thereafter	3,654
Total	13,823
Compensation agreements	'
Long-Term Contractual Obligations	'
Remaining fiscal year	3,223
2015	2,478
2016	494
2017	75
Total	6,270
Deferred compensation and other	'
Long-Term Contractual Obligations	'
Remaining fiscal year	41
2015	55
2016	43
2017	42
2018	36
Thereafter	27
Total	$244

Commitments_and_Contingencies_2

Commitments and Contingencies (Details 2)	0 Months Ended
	Aug. 02, 2011	Nov. 03, 2012	Dec. 31, 2012
	Byrne Medical Business	SPS Medical Supply Corp	Eagle Pure Water Systems, Inc.
Long-Term Contractual Obligations	'	'	'
Compensation agreement term	'3 years	'3 years	'3 years

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Components and changes in accumulated other comprehensive income (loss)	'	'
Balance at the beginning of the period	$10,977,000	$8,175,000
Other comprehensive income (loss) before reclassifications	-306,000	104,000
Income tax effect on other comprehensive income (loss) before reclassifications	12,000	-24,000
Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	48,000	55,000
Income tax effect on reclassification adjustments	-18,000	-21,000
Balance at the end of the period	10,713,000	8,289,000
Foreign Currency Translation Adjustments	'	'
Components and changes in accumulated other comprehensive income (loss)	'	'
Balance at the beginning of the period	11,080,000	8,385,000
Other comprehensive income (loss) before reclassifications	-273,000	122,000
Income tax effect on other comprehensive income (loss) before reclassifications	'	-31,000
Balance at the end of the period	10,807,000	8,476,000
Interest Rate Swap Agreements	'	'
Components and changes in accumulated other comprehensive income (loss)	'	'
Balance at the beginning of the period	-103,000	-210,000
Other comprehensive income (loss) before reclassifications	-33,000	-18,000
Income tax effect on other comprehensive income (loss) before reclassifications	12,000	7,000
Reclassification adjustments to interest expense for losses on interest rate swaps included in net income during the period	48,000	55,000
Income tax effect on reclassification adjustments	-18,000	-21,000
Balance at the end of the period	($94,000)	($187,000)

Operating_Segments_Details

Operating Segments (Details) (USD $)	3 Months Ended
Operating Segments (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Concentration risk	'	'
Consolidated net sales	$118,272,000	$99,681,000
Water Purification and Filtration	'	'
Concentration risk	'	'
Consolidated net sales	39,750,000	33,161,000
Dialysis	'	'
Concentration risk	'	'
Consolidated net sales	7,309,000	8,187,000
Healthcare Disposables	'	'
Concentration risk	'	'
Consolidated net sales	26,249,000	19,955,000
Segment sales \| Customer concentration \| Water Purification and Filtration \| DaVita	'	'
Concentration risk	'	'
Concentration risk (as a percent)	23.10%	'
Segment sales \| Customer concentration \| Water Purification and Filtration \| Another large dialysis provider	'	'
Concentration risk	'	'
Concentration risk (as a percent)	23.80%	'
Segment sales \| Customer concentration \| Dialysis \| DaVita	'	'
Concentration risk	'	'
Concentration risk (as a percent)	38.50%	'
Segment sales \| Customer concentration \| Healthcare Disposables \| Four customers	'	'
Concentration risk	'	'
Number of customers concentration risk	4	'
Concentration risk (as a percent)	55.60%	'
Net sales \| Customer concentration \| DaVita	'	'
Concentration risk	'	'
Concentration risk (as a percent)	10.10%	10.40%
Consolidated net sales	$11,988,000	$10,360,000
Net sales \| Customer concentration \| DaVita and another large dialysis provider	'	'
Concentration risk	'	'
Number of customers concentration risk	2	'
Concentration risk (as a percent)	18.10%	'
Net sales \| Customer concentration \| Four customers	'	'
Concentration risk	'	'
Concentration risk (as a percent)	12.30%	'

Operating_Segments_Details_2

Operating Segments (Details 2) (USD $)	3 Months Ended
Operating Segments (Details 2) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Information as to operating segments	'	'
Net sales	$118,272,000	$99,681,000
Operating income:	18,312,000	15,972,000
Interest expense, net	-644,000	-633,000
Income before income taxes	17,668,000	15,339,000
Operating Segments	'	'
Information as to operating segments	'	'
Operating income:	21,729,000	18,783,000
Endoscopy	'	'
Information as to operating segments	'	'
Net sales	43,613,000	36,679,000
Operating income:	8,184,000	7,676,000
Water Purification and Filtration	'	'
Information as to operating segments	'	'
Net sales	39,750,000	33,161,000
Operating income:	6,057,000	4,627,000
Healthcare Disposables	'	'
Information as to operating segments	'	'
Net sales	26,249,000	19,955,000
Operating income:	5,719,000	4,091,000
Dialysis	'	'
Information as to operating segments	'	'
Net sales	7,309,000	8,187,000
Operating income:	1,764,000	2,176,000
Other	'	'
Information as to operating segments	'	'
Net sales	1,351,000	1,699,000
Operating income:	5,000	213,000
General corporate	'	'
Information as to operating segments	'	'
General corporate expenses	($3,417,000)	($2,811,000)